US20040127738A1 - Method for curing cyanoacrylate adhesives - Google Patents
Method for curing cyanoacrylate adhesives Download PDFInfo
- Publication number
- US20040127738A1 US20040127738A1 US10/733,287 US73328703A US2004127738A1 US 20040127738 A1 US20040127738 A1 US 20040127738A1 US 73328703 A US73328703 A US 73328703A US 2004127738 A1 US2004127738 A1 US 2004127738A1
- Authority
- US
- United States
- Prior art keywords
- adhesive
- cyanoacrylate
- cyanoacrylate adhesive
- acid
- tocopherol
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 238000000034 method Methods 0.000 title claims abstract description 73
- 239000004830 Super Glue Substances 0.000 title claims abstract description 58
- 239000000853 adhesive Substances 0.000 claims abstract description 47
- 230000001070 adhesive effect Effects 0.000 claims abstract description 47
- FGBJXOREULPLGL-UHFFFAOYSA-N ethyl cyanoacrylate Chemical compound CCOC(=O)C(=C)C#N FGBJXOREULPLGL-UHFFFAOYSA-N 0.000 claims abstract description 47
- 239000003381 stabilizer Substances 0.000 claims abstract description 45
- 239000002253 acid Substances 0.000 claims description 36
- 230000001965 increasing effect Effects 0.000 claims description 18
- KRHYYFGTRYWZRS-UHFFFAOYSA-N Fluorane Chemical compound F KRHYYFGTRYWZRS-UHFFFAOYSA-N 0.000 claims description 14
- RAHZWNYVWXNFOC-UHFFFAOYSA-N Sulphur dioxide Chemical compound O=S=O RAHZWNYVWXNFOC-UHFFFAOYSA-N 0.000 claims description 14
- GVJHHUAWPYXKBD-UHFFFAOYSA-N d-alpha-tocopherol Natural products OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims description 12
- 125000000129 anionic group Chemical group 0.000 claims description 11
- 150000002148 esters Chemical class 0.000 claims description 11
- 238000004806 packaging method and process Methods 0.000 claims description 11
- -1 phenolic free radical Chemical class 0.000 claims description 10
- 229930003799 tocopherol Natural products 0.000 claims description 10
- 229960001295 tocopherol Drugs 0.000 claims description 10
- 239000011732 tocopherol Substances 0.000 claims description 10
- 235000010384 tocopherol Nutrition 0.000 claims description 10
- ZAKOWWREFLAJOT-CEFNRUSXSA-N D-alpha-tocopherylacetate Chemical compound CC(=O)OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-CEFNRUSXSA-N 0.000 claims description 9
- 230000000087 stabilizing effect Effects 0.000 claims description 9
- 229940042585 tocopherol acetate Drugs 0.000 claims description 9
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 claims description 9
- 239000002243 precursor Substances 0.000 claims description 8
- QYHFIVBSNOWOCQ-UHFFFAOYSA-N selenic acid Chemical compound O[Se](O)(=O)=O QYHFIVBSNOWOCQ-UHFFFAOYSA-N 0.000 claims description 8
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 claims description 6
- 150000001875 compounds Chemical class 0.000 claims description 6
- 238000011068 loading method Methods 0.000 claims description 6
- 230000008569 process Effects 0.000 claims description 5
- 230000001976 improved effect Effects 0.000 claims description 3
- 239000000203 mixture Substances 0.000 abstract description 41
- 239000000758 substrate Substances 0.000 abstract description 23
- 230000006872 improvement Effects 0.000 abstract description 5
- 238000004519 manufacturing process Methods 0.000 abstract description 5
- 239000000178 monomer Substances 0.000 description 60
- 229920001651 Cyanoacrylate Polymers 0.000 description 37
- 229920000642 polymer Polymers 0.000 description 37
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 36
- MWCLLHOVUTZFKS-UHFFFAOYSA-N Methyl cyanoacrylate Chemical compound COC(=O)C(=C)C#N MWCLLHOVUTZFKS-UHFFFAOYSA-N 0.000 description 22
- 239000000126 substance Substances 0.000 description 22
- 238000011282 treatment Methods 0.000 description 18
- 239000000654 additive Substances 0.000 description 17
- 230000015556 catabolic process Effects 0.000 description 17
- NLCKLZIHJQEMCU-UHFFFAOYSA-N cyano prop-2-enoate Chemical class C=CC(=O)OC#N NLCKLZIHJQEMCU-UHFFFAOYSA-N 0.000 description 17
- 238000006731 degradation reaction Methods 0.000 description 17
- 238000006116 polymerization reaction Methods 0.000 description 17
- 230000000694 effects Effects 0.000 description 16
- CQVWXNBVRLKXPE-UHFFFAOYSA-N 2-octyl cyanoacrylate Chemical compound CCCCCCC(C)OC(=O)C(=C)C#N CQVWXNBVRLKXPE-UHFFFAOYSA-N 0.000 description 15
- 239000000047 product Substances 0.000 description 15
- 239000003708 ampul Substances 0.000 description 13
- 238000006243 chemical reaction Methods 0.000 description 13
- 238000012360 testing method Methods 0.000 description 12
- 150000007513 acids Chemical class 0.000 description 11
- 230000015572 biosynthetic process Effects 0.000 description 11
- 230000007246 mechanism Effects 0.000 description 11
- 239000003999 initiator Substances 0.000 description 9
- 208000027418 Wounds and injury Diseases 0.000 description 8
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 7
- 239000011521 glass Substances 0.000 description 7
- 230000003301 hydrolyzing effect Effects 0.000 description 7
- 238000000338 in vitro Methods 0.000 description 7
- 238000010539 anionic addition polymerization reaction Methods 0.000 description 6
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 6
- 238000002955 isolation Methods 0.000 description 6
- 239000000463 material Substances 0.000 description 6
- 150000003254 radicals Chemical class 0.000 description 6
- 238000003786 synthesis reaction Methods 0.000 description 6
- 239000003795 chemical substances by application Substances 0.000 description 5
- 229920001577 copolymer Polymers 0.000 description 5
- 239000006185 dispersion Substances 0.000 description 5
- 239000012530 fluid Substances 0.000 description 5
- 238000005755 formation reaction Methods 0.000 description 5
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 5
- 239000003112 inhibitor Substances 0.000 description 5
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 5
- 230000004048 modification Effects 0.000 description 5
- 238000012986 modification Methods 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 4
- 230000002378 acidificating effect Effects 0.000 description 4
- 150000008064 anhydrides Chemical class 0.000 description 4
- 230000000368 destabilizing effect Effects 0.000 description 4
- 238000004821 distillation Methods 0.000 description 4
- 238000001914 filtration Methods 0.000 description 4
- 230000002028 premature Effects 0.000 description 4
- 239000002516 radical scavenger Substances 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 238000003860 storage Methods 0.000 description 4
- MGSRCZKZVOBKFT-UHFFFAOYSA-N thymol Chemical compound CC(C)C1=CC=C(C)C=C1O MGSRCZKZVOBKFT-UHFFFAOYSA-N 0.000 description 4
- MLIREBYILWEBDM-UHFFFAOYSA-M 2-cyanoacetate Chemical compound [O-]C(=O)CC#N MLIREBYILWEBDM-UHFFFAOYSA-M 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical group OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 3
- 238000010521 absorption reaction Methods 0.000 description 3
- 230000000996 additive effect Effects 0.000 description 3
- 150000001412 amines Chemical class 0.000 description 3
- 239000003963 antioxidant agent Substances 0.000 description 3
- 235000006708 antioxidants Nutrition 0.000 description 3
- 238000013459 approach Methods 0.000 description 3
- 238000009835 boiling Methods 0.000 description 3
- 238000010504 bond cleavage reaction Methods 0.000 description 3
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 3
- 239000006227 byproduct Substances 0.000 description 3
- 230000000052 comparative effect Effects 0.000 description 3
- 239000007857 degradation product Substances 0.000 description 3
- 238000004090 dissolution Methods 0.000 description 3
- 230000001747 exhibiting effect Effects 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 229910052739 hydrogen Inorganic materials 0.000 description 3
- 239000001257 hydrogen Substances 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 238000011065 in-situ storage Methods 0.000 description 3
- 230000000977 initiatory effect Effects 0.000 description 3
- RPQUGMLCZLGZTG-UHFFFAOYSA-N octyl cyanoacrylate Chemical compound CCCCCCCCOC(=O)C(=C)C#N RPQUGMLCZLGZTG-UHFFFAOYSA-N 0.000 description 3
- 125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 3
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N phenol group Chemical group C1(=CC=CC=C1)O ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 3
- 239000004814 polyurethane Substances 0.000 description 3
- 229920002635 polyurethane Polymers 0.000 description 3
- 230000007017 scission Effects 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 238000001179 sorption measurement Methods 0.000 description 3
- 238000011105 stabilization Methods 0.000 description 3
- 230000000699 topical effect Effects 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- 238000010626 work up procedure Methods 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- QIGBRXMKCJKVMJ-UHFFFAOYSA-N Hydroquinone Chemical compound OC1=CC=C(O)C=C1 QIGBRXMKCJKVMJ-UHFFFAOYSA-N 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- PPBRXRYQALVLMV-UHFFFAOYSA-N Styrene Chemical compound C=CC1=CC=CC=C1 PPBRXRYQALVLMV-UHFFFAOYSA-N 0.000 description 2
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 2
- 239000005844 Thymol Substances 0.000 description 2
- 239000002696 acid base indicator Substances 0.000 description 2
- 230000032683 aging Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 125000002704 decyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
- 230000009977 dual effect Effects 0.000 description 2
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
- 230000007062 hydrolysis Effects 0.000 description 2
- 238000006460 hydrolysis reaction Methods 0.000 description 2
- SJWFXCIHNDVPSH-UHFFFAOYSA-N octan-2-ol Chemical compound CCCCCCC(C)O SJWFXCIHNDVPSH-UHFFFAOYSA-N 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 229920003229 poly(methyl methacrylate) Polymers 0.000 description 2
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- MCAHWIHFGHIESP-UHFFFAOYSA-N selenous acid Chemical class O[Se](O)=O MCAHWIHFGHIESP-UHFFFAOYSA-N 0.000 description 2
- 239000002002 slurry Substances 0.000 description 2
- GCLGEJMYGQKIIW-UHFFFAOYSA-H sodium hexametaphosphate Chemical compound [Na]OP1(=O)OP(=O)(O[Na])OP(=O)(O[Na])OP(=O)(O[Na])OP(=O)(O[Na])OP(=O)(O[Na])O1 GCLGEJMYGQKIIW-UHFFFAOYSA-H 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 230000006641 stabilisation Effects 0.000 description 2
- 150000003460 sulfonic acids Chemical class 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 229960000790 thymol Drugs 0.000 description 2
- PRZSXZWFJHEZBJ-UHFFFAOYSA-N thymol blue Chemical compound C1=C(O)C(C(C)C)=CC(C2(C3=CC=CC=C3S(=O)(=O)O2)C=2C(=CC(O)=C(C(C)C)C=2)C)=C1C PRZSXZWFJHEZBJ-UHFFFAOYSA-N 0.000 description 2
- 238000004448 titration Methods 0.000 description 2
- 238000005809 transesterification reaction Methods 0.000 description 2
- 230000000007 visual effect Effects 0.000 description 2
- USLREAHVHGEBQD-UHFFFAOYSA-N 2-cyanoacetic acid;formaldehyde Chemical compound O=C.OC(=O)CC#N USLREAHVHGEBQD-UHFFFAOYSA-N 0.000 description 1
- PYSRRFNXTXNWCD-UHFFFAOYSA-N 3-(2-phenylethenyl)furan-2,5-dione Chemical compound O=C1OC(=O)C(C=CC=2C=CC=CC=2)=C1 PYSRRFNXTXNWCD-UHFFFAOYSA-N 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 1
- JOYRKODLDBILNP-UHFFFAOYSA-N Ethyl urethane Chemical compound CCOC(N)=O JOYRKODLDBILNP-UHFFFAOYSA-N 0.000 description 1
- 239000005977 Ethylene Substances 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 1
- BELBBZDIHDAJOR-UHFFFAOYSA-N Phenolsulfonephthalein Chemical compound C1=CC(O)=CC=C1C1(C=2C=CC(O)=CC=2)C2=CC=CC=C2S(=O)(=O)O1 BELBBZDIHDAJOR-UHFFFAOYSA-N 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 206010040880 Skin irritation Diseases 0.000 description 1
- DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 description 1
- 229920000147 Styrene maleic anhydride Polymers 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- XTXRWKRVRITETP-UHFFFAOYSA-N Vinyl acetate Chemical compound CC(=O)OC=C XTXRWKRVRITETP-UHFFFAOYSA-N 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 229920004482 WACKER® Polymers 0.000 description 1
- 238000010306 acid treatment Methods 0.000 description 1
- 229920006397 acrylic thermoplastic Polymers 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000002318 adhesion promoter Substances 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 238000005904 alkaline hydrolysis reaction Methods 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 150000001450 anions Chemical class 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 238000010420 art technique Methods 0.000 description 1
- KGQLBLGDIQNGSB-UHFFFAOYSA-N benzene-1,4-diol;methoxymethane Chemical compound COC.OC1=CC=C(O)C=C1 KGQLBLGDIQNGSB-UHFFFAOYSA-N 0.000 description 1
- 239000012620 biological material Substances 0.000 description 1
- 239000007767 bonding agent Substances 0.000 description 1
- UDSAIICHUKSCKT-UHFFFAOYSA-N bromophenol blue Chemical compound C1=C(Br)C(O)=C(Br)C=C1C1(C=2C=C(Br)C(O)=C(Br)C=2)C2=CC=CC=C2S(=O)(=O)O1 UDSAIICHUKSCKT-UHFFFAOYSA-N 0.000 description 1
- QXJJQWWVWRCVQT-UHFFFAOYSA-K calcium;sodium;phosphate Chemical compound [Na+].[Ca+2].[O-]P([O-])([O-])=O QXJJQWWVWRCVQT-UHFFFAOYSA-K 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 230000001010 compromised effect Effects 0.000 description 1
- 238000006482 condensation reaction Methods 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 239000000356 contaminant Substances 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- OBRMNDMBJQTZHV-UHFFFAOYSA-N cresol red Chemical compound C1=C(O)C(C)=CC(C2(C3=CC=CC=C3S(=O)(=O)O2)C=2C=C(C)C(O)=CC=2)=C1 OBRMNDMBJQTZHV-UHFFFAOYSA-N 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- KWKVJEUILVQMRR-UHFFFAOYSA-N decyl 2-cyanoprop-2-enoate Chemical compound CCCCCCCCCCOC(=O)C(=C)C#N KWKVJEUILVQMRR-UHFFFAOYSA-N 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- FPVGTPBMTFTMRT-UHFFFAOYSA-L disodium;2-amino-5-[(4-sulfonatophenyl)diazenyl]benzenesulfonate Chemical compound [Na+].[Na+].C1=C(S([O-])(=O)=O)C(N)=CC=C1N=NC1=CC=C(S([O-])(=O)=O)C=C1 FPVGTPBMTFTMRT-UHFFFAOYSA-L 0.000 description 1
- LFJLAWZRNOKTDN-UHFFFAOYSA-N dodecyl 2-cyanoprop-2-enoate Chemical compound CCCCCCCCCCCCOC(=O)C(=C)C#N LFJLAWZRNOKTDN-UHFFFAOYSA-N 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000001700 effect on tissue Effects 0.000 description 1
- 229940024464 emollients and protectives zinc product Drugs 0.000 description 1
- 238000005538 encapsulation Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 125000005448 ethoxyethyl group Chemical group [H]C([H])([H])C([H])([H])OC([H])([H])C([H])([H])* 0.000 description 1
- 229940053009 ethyl cyanoacrylate Drugs 0.000 description 1
- 239000005038 ethylene vinyl acetate Substances 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000000763 evoking effect Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 235000019233 fast yellow AB Nutrition 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- WOLATMHLPFJRGC-UHFFFAOYSA-N furan-2,5-dione;styrene Chemical compound O=C1OC(=O)C=C1.C=CC1=CC=CC=C1 WOLATMHLPFJRGC-UHFFFAOYSA-N 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000009931 harmful effect Effects 0.000 description 1
- XDZLHTBOHLGGCJ-UHFFFAOYSA-N hexyl 2-cyanoprop-2-enoate Chemical class CCCCCCOC(=O)C(=C)C#N XDZLHTBOHLGGCJ-UHFFFAOYSA-N 0.000 description 1
- 229920001903 high density polyethylene Polymers 0.000 description 1
- 239000004700 high-density polyethylene Substances 0.000 description 1
- 229920001519 homopolymer Polymers 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 239000002198 insoluble material Substances 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- QRWOVIRDHQJFDB-UHFFFAOYSA-N isobutyl cyanoacrylate Chemical compound CC(C)COC(=O)C(=C)C#N QRWOVIRDHQJFDB-UHFFFAOYSA-N 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- FPYJFEHAWHCUMM-UHFFFAOYSA-N maleic anhydride Chemical compound O=C1OC(=O)C=C1 FPYJFEHAWHCUMM-UHFFFAOYSA-N 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000037353 metabolic pathway Effects 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 239000003607 modifier Substances 0.000 description 1
- 239000002808 molecular sieve Substances 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 229960003531 phenolsulfonphthalein Drugs 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 239000004014 plasticizer Substances 0.000 description 1
- 229920001200 poly(ethylene-vinyl acetate) Polymers 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 229920000728 polyester Polymers 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 229920001721 polyimide Polymers 0.000 description 1
- 239000009719 polyimide resin Substances 0.000 description 1
- 239000004926 polymethyl methacrylate Substances 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 229920000131 polyvinylidene Polymers 0.000 description 1
- 229910000027 potassium carbonate Inorganic materials 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 150000004053 quinones Chemical class 0.000 description 1
- 238000010526 radical polymerization reaction Methods 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 238000004626 scanning electron microscopy Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 150000004760 silicates Chemical class 0.000 description 1
- 230000036556 skin irritation Effects 0.000 description 1
- 231100000475 skin irritation Toxicity 0.000 description 1
- URGAHOPLAPQHLN-UHFFFAOYSA-N sodium aluminosilicate Chemical compound [Na+].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O URGAHOPLAPQHLN-UHFFFAOYSA-N 0.000 description 1
- 235000010267 sodium hydrogen sulphite Nutrition 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 230000003595 spectral effect Effects 0.000 description 1
- 230000007480 spreading Effects 0.000 description 1
- 238000003892 spreading Methods 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 150000003457 sulfones Chemical class 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- ISXSCDLOGDJUNJ-UHFFFAOYSA-N tert-butyl prop-2-enoate Chemical compound CC(C)(C)OC(=O)C=C ISXSCDLOGDJUNJ-UHFFFAOYSA-N 0.000 description 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
- 238000012719 thermal polymerization Methods 0.000 description 1
- 229920001169 thermoplastic Polymers 0.000 description 1
- 239000004634 thermosetting polymer Substances 0.000 description 1
- 239000004416 thermosoftening plastic Substances 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 239000003106 tissue adhesive Substances 0.000 description 1
- 230000036269 ulceration Effects 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 239000011787 zinc oxide Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
- C09J—ADHESIVES; NON-MECHANICAL ASPECTS OF ADHESIVE PROCESSES IN GENERAL; ADHESIVE PROCESSES NOT PROVIDED FOR ELSEWHERE; USE OF MATERIALS AS ADHESIVES
- C09J4/00—Adhesives based on organic non-macromolecular compounds having at least one polymerisable carbon-to-carbon unsaturated bond ; adhesives, based on monomers of macromolecular compounds of groups C09J183/00 - C09J183/16
Definitions
- This invention relates broadly to a method of treating stabilized cyanoacrylate adhesives prior to their application to a substrate, particularly with reference to medical procedures using such adhesives.
- Woodward et al. reported histotoxicity of these monomers in rat tissue. S. C. Woodward, et al., ANN. SURG. Vol. 162, July 1965. The study involved in situ polymerization of three cyanoacrylate monomers: methyl, hexyl, decyl. It was reported that histotoxic effects were greatest with methyl and decreased with the other two monomers.
- the first observed degradation product turned out to be one of the starting materials, i.e., formaldehyde.
- formaldehyde In vitro studies have shown that the polymers degrade via hydrolytic scission in homogeneous as well as heterogeneous conditions. F. Leonard et al., J.A.P.S., Vol. 10: 259, 1966. These degradation products were confirmed to be formaldehyde and the corresponding cyanoacetate.
- the conditions of solution degradation affected the consequent rates, namely, under neutral conditions rates decreased as the homologous series was ascended while alkaline conditions increased all rates.
- Rates of degradation on ethyl, butyl, and hexyl cyanoacrylates were evaluated with regards to molecular weights, concentrations, and side chain structures.
- the method employed buffered systems of pH ranges from 5.97 to 7.88. As expected, the rates increased with increasing pH. Scanning electron microscopy of the degraded polymer indicated that reaction occurs at the surfaces and not internally through diffusion. It was postulated that the greater the length of the—alkyl side chain, the more protection provided to the labile hydroxyl end of the polymer chain. This in turn would provide greater resistance to degradation of the polymer. Degradation rates do in fact correspond to chain length protection.
- the relative rates of degradation for hexyl, butyl, and ethyl were, respectively, 1.0, 1.36, 9.55.
- U.S. Pat. No. 3,995,641 to Kronenthal et al. discusses the novelty of modified cyanoacrylates, namely, carbalkoxyalkyl cyanoacrylates.
- the patent discloses their usefulness as a tissue adhesive in surgical applications. The presumed superiority of these products was attributable to the rapid hydrolytic decay and concurrent low degree of histotoxicity. Since no data is presented regarding formaldehyde evolution, it is presumed that the hydrolysis mechanism does not scission the polymer to generate it.
- U.S. Pat. No. 5,254,132 to Bartley et al. discloses the use of a hybrid method of surgical application of cyanoacrylates. It discloses a combination of sutures and adhesive such as to be mutually isolated from each other, but to both support the re-growth of the tissue in the wound area.
- the '132 patent addresses the issue of insuring no contact of adhesive in the suture area so as to assure no inclusions of the cyanoacrylate.
- the disclosed method appears to be awkward and cumbersome, and requires a very effective and controlled dispensing of the adhesive without contacting the suture. Additional concern is indicated as a suggestion is made to employ a solvent (acetone) if any surgical instrument happens to be bonded inadvertently to the treated area.
- a formaldehyde scavenger such as, sodium bisulfite.
- the various compositions were evaluated via in-vitro experimentation. The examples presented all had a presumably excessive level of scavenger.
- the representative compositions had loadings of 20% of a scavenging agent that was designed to offset formaldehyde emissions that were at 0.1%.
- in-vitro and in vivo conditions are not identical and certainly not in this instance.
- the in-vitro conditions presented in the '687 patent do not factor in the dynamic conditions in living tissue.
- the surgically treated area would be under continuous and changing fluids as the organ attempts to bring in the necessary biocomponents to heal the traumatized tissue. As such, it would not be expected that the scavenger/formaldehyde ratio would be maintained as it was in the in-vitro state. It could be speculated that the use of such high loadings of any fluid solubilized additives would contribute to greater formaldehyde emissions. This can be assumed to be a consequence of dissolution of the additives resulting in cavities in the polymer, thereby promoting greater surface area for hydrolytic degradation.
- U.S. Pat. No. 5,403,591 to Tighe et al. relates to the use of cyanoacrylates for treatment of skin irritations that progress to ulcerations. It would be assumed that these conditions could be considered wound formations, e.g., see U.S. Pat. No. 3,995,641.
- U.S. Pat. Nos. 5,928,611 to Leung, 5,981,621 to Clark et al., 6,099,807 to Leung, 6,217,603 to Clark et al. describe methods of inducing cure of cyanoacrylates bypassing the adhesive through a porous applicator tip containing substances that initiate the polymerization. These substances co-elute and dissolve into the adhesive as it is forced through the porous tip.
- U.S. Pat. No. 6,143,352 to Clark et al. describes methods of altering the pH environment of cyanoacrylates in order to attenuate or accelerate the rate of hydrolytic degradation by uses of acid and alkaline additives.
- the formulation of acidic modifiers is problematic as they tend to inhibit the primary characteristic of these materials, namely, rapid cure on application to tissue.
- Data is presented on effects of acidic compositions on previously cured cyanoacrylates, not on in situ applied compositions.
- compositions may induce polymerization by creating a greater number of initiation sites and or orientation of the monomer for more facile polymerizations.
- Other plausible mechanisms can be evoked, but the fact remains that the added materials become a part of the composition (undesirable for many medical applications). As such, these chemical inclusions may elicit unfavorable reactions in the cured state.
- the use of pH-based accelerators may contribute to the alkaline hydrolysis of the cyanoacrylate polymer.
- additives for the cured adhesives are additives formulated into the synthesized monomers.
- the synthetic route for monomer production relies on two principal groups of stabilizers. The first group is chosen from substances capable of preventing free radical polymerization and the second group inhibits the anionic polymerization.
- the critical step in the production of these monomers relies on the high temperature thermal degradation of the polymer generated from the formaldehyde-cyanoacetate reaction. These temperatures span the range of 150° C. to excesses of 200° C. Under ideal conditions, this polymer will undergo a clean unzipping reaction that releases the cyanoacrylate monomer. This begins to take place in the lower temperature regions and must be gradually elevated to extract the increasingly difficult boiling off of the monomer. Elevation of the temperature is necessary as byproducts form and increasingly hamper the volatilization of the desired monomer.
- retarders or inhibitors are added at the beginning of this process. These substances react with free radicals to form a stable unreactive species, thereby halting the thermal polymerization typical of vinyl monomers.
- Quinones are the most often used substances in this group. Typical, but not exclusive, are hydroquinone and methyl ether hydroquinone. The presence of these additives is most critical in the monomer-polymer mix in the reaction vessel. Once the monomer is vaporized, it is quickly cooled to ambient conditions as it is distilled over to a suitable receiver.
- the second group of stabilizers are used to prevent the anionic polymerization of the monomer in the reaction vessel as well as the vapor and collected liquid monomer in the receiver.
- Typical, and again, not exclusive, are the sulfonic acids and sulfur dioxide.
- acidic substances are chosen to effect stabilization not only during the production of these monomers but further for stabilization during storage.
- an object of the present invention to provide a method for increasing the shelf life of a cyanoacrylate adhesive by increasing the stability of the adhesive.
- the method includes treating packaging for containment of the cyanoacrylate adhesive or precursors to the cyanoacrylate adhesive with a strong acid.
- the cyanoacrylate adhesive or precursor to the cyanoacrylate adhesive is then introduced to the packaging.
- ester of tocopherol has a concentration in the range of approximately 5% to approximately 15% by weight.
- the method is achieved by treating the cyanoacrylate adhesive with structures functionalized with both free radical and anionic inhibition in the same molecule.
- the treating compounds are titration indicators, also referred to as acid-base indicators.
- the levels of limitations are defined as sufficient to provide practical shelf life as well as acceptable utility in cyanoacrylate applications.
- the present invention generally relates to a method for curing reactive monomeric cyanoacrylates to undergo macromolecular formations via appropriate modification of anionic stabilizer levels in a manner permitting utilization of the resulting adhesives in the treatment of human, or animal, tissue and/or flesh, required to be otherwise sealed or sutured, or otherwise protected from its surroundings. While certain distinctions may be drawn between the usage of the terms “flesh” and “tissue” within the scientific community, the terms are used herein interchangeably as referring to a general substrate upon which those skilled in the art would understand the present adhesive to be utilized within the medical field for the treatment of patients. Without being bound to a specific mechanism, such modification of the anionic stabilzer levels chemically and/or physically removes stabilizing agents so the present method allows for reformulation of compositions capable of reasonable cure speeds without external anionic initiators.
- the present method generally includes the steps of providing a long shelf life stable adhesive composition comprising cyanoacrylate adhesive and excess stabilizing agent(s), removing excess stabilizing agent(s) from the adhesive composition, re-stabilizing and presenting a substrate to receive at least a portion of the cyanoacrylate adhesive composition and applying the cyanoacrylate adhesive portion to the substrate.
- Cyanoacrylate adhesives that may be used in accordance with the present invention, comprise one or more monomers having the following general structure:
- the various methods for the synthesis of these monomers generally require the addition of acids and free radical inhibitors during the monomer synthesis.
- the free radical inhibitors prevent premature polymerization during the thermal unzipping reaction as well as the follow-up distillation step(s).
- the acid additives are necessary to prevent premature polymerization during work-up and storage of these compositions.
- Prior art techniques rely upon pretreatment of the substrate with, for example, alkaline and/or organic soluble amines that are intended to initiate the anionic polymerization by dissolution into the adhesive. This approach is apparently based on the view that as the mass of the side chain group increases, the polymerizability drops off. This is apparent, as all current techniques rely on overriding the excess stabilizer levels.
- Alternative prior art methods employ a solution of these initiators being sprayed over the adhesive after it has been applied to the substrate. The other variant of this soluble initiator method are those referenced above incorporating the initiator in the porous applicator tip.
- This present method achieves this goal by removing stabilizers in cyanoacrylate adhesives prior to their application to substrates. This renders the resultant purified compositions highly susceptible to polymerizations when applied to the substrates. Again, without being bound to any single specific mechanism, this process relies on a combination of physical adsorption/absorption, chemical reaction, and hydrogen bonding of the acid group(s) onto particulate surfaces. It is necessary to have the acid removing particulate substances, in fluid contact with the excessively stabilized monomer(s), be insoluble or otherwise isolatable from the monomers, such as by filtration, centrifugation, phasing out, membrane separation, or other appropriate isolating mechanism. The requisite is the isolation of the acids or other stabilizers from the monomers.
- Substances exhibiting these mechanisms encompass polymers capable of forming hydrogen bonds with the stabilizing acids.
- These polymeric materials can have carbonyl, hydroxyl, amide, carboxylic, amine, ether, anhydride, ester, urethane, sulfone or other structures or combination structures capable of coupling or otherwise fixing the acid stabilizer to the isolatable substances.
- These polymeric materials can also be inorganic such as silicates.
- Other contemplated particulates are those in which the stabilizers are selectively trapped in zeolytic substances or otherwise caged in molecular sieves.
- Chemical isolation can be achieved by, for example, reactive contact with anhydride structures such as on copolymers containing maleic anhydride. It is postulated that the anhydride structure reacts to form an anhydride link with the mobile (stabilizing) acid and a carboxylic group, both being bound to the polymer chain; an example for this being maleic anhydride copolymers of styrene and ethylene.
- cyanoacrylate adhesives for medical applications in accordance with the invention, they are stored in a device that houses a crushable ampoule containing such adhesives.
- Such ampoule containing devices may be constructed of any number of materials that can be shaped or molded or otherwise fabricated to contain the adhesive and ampoule.
- the application devices are preferably manufactured from such materials as to effect a resilient wall capable of transmitting pressure to the crushable ampoule without loss of its containment properties.
- These application devices advantageously further comprise a filtering component and nozzle for application of the filtered adhesive to the substrate, for example, tissue of the patient being treated. Examples of application devices which may be used in accordance with the present method are disclosed in detail in the '226 application which, as discussed above, is incorporated herein by reference.
- the application devices can also be designed to apply the product in a continuous manner.
- An example of such a device is one that incorporates a reservoir of the appropriate adhesive feeding through a valving mechanism, thereby providing a source of adhesive without an ampoule.
- cyanoacrylate is contained in appropriate vessels such as glass or high-density polyethylene. These containers may be pretreated so as to effect useful shelf life. Reference again is made to those familiar with the art and patents delineating the various methods to achieve this treatment. Typically a container would hold 2-5 grams of product to provide many topical applications with appropriate disposable applicators such as pipettes.
- one of the above described devices houses 2-octyl cyanoacrylate which has been previously treated with poly(vinyl pyrrolidone/vinyl acetate) copolymer.
- the ampoule is crushed and the contents are then expressed through the appropriate filter and dispenser tip onto the substrate, specifically human, or animal tissue, or skin.
- the application is accomplished in such fashion as to prevent encapsulation of adhesive by any surrounding tissue. Though ultimately these inclusions are degraded and excreted, it is most desirable to minimize this occurrence to maximize reconstitution of the surrounding tissue.
- the need to assure this minimization was noted in U.S. Pat. No. 3,667,472 which pointed out the requisite to bridge the wound without diffusing into it. This was accomplished by bringing the wound edges together followed by application so as to effect a bridging over the wound to circumvent necrosis and irritation by this technique.
- a second preferred embodiment utilizes the above-described devices containing decyl cyanoacrylate.
- a third preferred embodiment utilizes the above-described devices containing dodecyl cyanoacrylate.
- a fourth preferred embodiment includes the above with combinations of cyanoacrylate monomers to achieve control over the rate of hydrolytic degradation so as to improve compatibility with tissue by control of formaldehyde emissions.
- the invention employs vinyl pyrrolidone polymers and copolymers to remove stabilizers from the cyanoacrylate adhesives formulation.
- These particulate agents are combined with the monomer adhesive in mutual contact until the adhesive is destabilized, whereupon the adhesive becomes isolated from the destabilizing agent by various means such as to effect isolation of the adhesive from the destabilizing component. Once isolated, the adhesive is restabilized at reduced levels so as to effect timely cure rates in the 5 seconds to approximately one minute range. It should further be understood that these particulate agents may have some degree of solubility and therefore may pass through along with the adhesive onto the substrate. It is only a requisite that enough excess stabilizer is left behind so as to provide the desirable speed of cure.
- re-stabilization is also desirable in order to provide a balance between speed of cure and shelf life.
- oligomeric or low molecular weight fractions may indeed be somewhat soluble in the cyanoacrylate adhesives but still be effective in producing a desirable adhesive composition.
- a novel improvement in shelf life of these adhesives has been observed with the use of stabilizers having both phenolic and acidic functionalities in the same structure.
- These types of substances are typically recognized as acid-base indicators or titration indicators.
- the following compounds are contemplated for use in accordance with a preferred embodiment of the present invention: thymol blue, trisulphonated napthol, phenolsulfonapthalein, pyrochatechol violet, acid yellow, bromophenol blue, phenol red, and cresol red.
- An additional benefit is the inherent color imparted to some of the compositions utilizing the stabilizers. These can serve as visual indicators of coverage on the substrate.
- concentrations of these dual function stabilizers are expected to be effective in ranges typically associated with sulfur dioxide, sulfonic acids, and other acids as well as in the ranges associated with the phenolic stabilizers for these monomers as is known in the art. They may further act synergistically with stabilizers of the prior art.
- the device of the invention is one that (a) delivers the cyanoacrylate adhesive of convenient viscosity, (b) contains a porous segment for the containment of the ampoule and other components so as to permit the release of the adhesive with no particulate components being released onto the substrate to which it is applied, (c) delivers the adhesive through a nozzle applicator tip configured for appropriate application onto the substrate, and (d) can be used with other monomer formulations prior to application to effect the desired result such as polymerizations to produce various thermoplastic and thermoset resins of both organic and inorganic nature.
- All of preferred embodiments disclosed in accordance with the present invention should be understood to further include all of the various additives useful in the alteration and improvement to cyanoacrylate adhesives as would make them suitable for placement into the above devices, substrates, and modifications to these and similar devices.
- additives useful in the alteration and improvement to cyanoacrylate adhesives as would make them suitable for placement into the above devices, substrates, and modifications to these and similar devices.
- These can include plasticizers, stabilizers, surface insensitive additives, tougheners, thickeners, adhesion promoters, other monomers, comonomers, and other such compositions as would be evident to those familiar with the cyanoacrylate adhesives art.
- a quantity of particulate destabilizing agent (5 grams) in the form of vinyl pyrrolidone vinyl acetate copolymer is blended with (25 grams) 2-octyl cyanoacrylate for a period of 24 hours.
- the resultant slurry is filtered to effectively remove the destabilizing agent and is restabilzed at a level to achieve the desired cure speed for the following test.
- 6 grams of the treated monomer is blended with 0.012 grams of pretreated monomer.
- a glass ampoule is charged with 0.5 grams of treated monomer and sealed with a gas flame.
- the ampoule is inserted into a tubular device referred to as a Tandem Dropper supplied by James Alexander Company of Blairstown, N.J., that also provided unsealed ampoules.
- a Tandem Dropper supplied by James Alexander Company of Blairstown, N.J.
- the dispenser tip press fits onto the end of the Tandem Dropper after insertion of the sealed ampoule.
- the assembled device is squeezed to effect rupture of the ampoule. Pressure is applied so as to exude a drop of adhesive through the filtering tip. The drop is applied to skin and timed to determine when the film has undergone cure to a non-tacky surface.
- the 2-octyl cyanoacrylate undergoes cure in 10-20 seconds upon application to skin on the back of the hand. This contrasts with untreated 2-octyl cyanoacrylate which shows no sign of cure up to 3 minutes whereupon the test is terminated.
- a 10 milliliter glass vial is charged with 0.5 grams of activated charcoal Calgon WPX, sourced from Calgon Carbon Corp. of Pittsburgh Pa.
- a 6.0 gram charge of 2-octyl cyanoacrylate which is mixed for a period of 30 minutes.
- the resulting dispersion is filtered to isolate the cyanoacylate into a small ampoule.
- a test of cure speed on skin of the isolated monomer results in the formation of a protective film in 10 to 20 seconds in a manner similar to example 1 above.
- a 3 milliliter test tube is charged with 0.016 grams of anhydrous potassium carbonate and 2.030 grams of 2-octyl cyanoacrylate which is then sealed and shaken for approximately 2 hours. It is stored for 17 days. A sample is removed and applied to the skin with a consequent film cure in a range of 110 to 120 seconds.
- Example 3 is repeated with a higher loading of the anhydrous carbonate: 0.27 grams and 2.46 grams of 2-octyl cyanoacrylate.
- the test tube is stored for 15 days whereupon a test of cure exhibits film formation in 120 seconds.
- a 50 milliliter flask is charged and sealed with 1.5 grams of polyvinyl alcohol granules (BP-05) and 18.5 grams of 2-octyl cyanoacrylate.
- the dispersion is intermittently shaken for a period of 48 hours due to the more coarse nature of the polymer.
- a sample is taken and tested on skin to show a cure of film in 90 to 100 seconds.
- a flask is charged and sealed with 1.0 grams of ethylene-vinyl acetate copolymer RP251 (Wacker Polysystems) and 18.5 grams of 2-octyl cyanaocrylate. The dispersion is intermittently shaken for 48 hours prior to the skin test. Upon testing the treated monomer cured in approximately 100 seconds
- Example 6 is repeated with RP140, a vinyl acetate homopolymer. The resultant treated monomer gave a cure after 130 seconds.
- a 10 milliliter flask is charged and sealed with 1.0 grams of poly(methyl methacrylate) (Rhohadon M449, Rohmtech Inc.) and 6 grams of 2-octyl cyanaocrylate. After intermittent shaking for 24 hours, the dispersion is filtered and the isolated monomer is tested to reveal a film formation in 30 to 35 seconds.
- poly(methyl methacrylate) Rhohadon M449, Rohmtech Inc.
- a 10 milliliter flask is charged and sealed with 0.5 grams of zinc oxide (AZO66, US Zinc Products Inc.) and 6 grams of 2-octyl cyanoacrylate. After shaking the dispersion for 30 minutes, subsequent filtration and testing on skin gave a cure in 50 to 60 seconds.
- zinc oxide AZO66, US Zinc Products Inc.
- 2-octyl cyanoacrylate After shaking the dispersion for 30 minutes, subsequent filtration and testing on skin gave a cure in 50 to 60 seconds.
- a 10 milliliter flask is charged and sealed with 1.6 grams of glass spheres (Class 4A size 203 from Cataphote Corp.) and 4.4 grams of 2-octyl cyanoacrylate. The mix was shaken for 2 hours prior to testing. The sampled droplet was spread on skin giving a 60 second cure.
- glass spheres Class 4A size 203 from Cataphote Corp.
- a two ounce, opaque polyethylene bottle is charged with 0.57 grams of vinyl pyrrolidone vinyl acetate copolymer and 30 grams of 2-octyl cyanoacrylate.
- the container is shaken for five minutes and stored for 3 months.
- a sample was taken and passed through a 0.2 micron filter with a 1 milliliter syringe.
- Application onto skin gave a very rapid cure of 10-15 seconds with noticeable warmth due to the more rapid polymerization.
- these additives can be left in contact with the cyanoacrylate with no apparent detriment to the shelf life and cure of the final product. It is further evident that these products can be kept without the need to isolate and store in glass ampoules. This further leads to the capability of large reservoirs of product to be dispensable through a disposable fibrous or porous tip. This is particularly advantageous in procedures where quantities necessary exceed the capacity of the crushable ampoules.
- the only limitations to the various treatments is the ability to isolate a practical level of cyanoacrylate monomer, i.e., that concentrations even at levels creating slurries can be filtered off to achieve economic quantities. These examples serve to show the extensive applicability of the primary requisite: to remove excessive stabilizer(s).
- hydrofluoric acid is used to improve the shelf life of cyanoacrylate adhesives, as well as their precursors, produced in accordance with the present invention.
- the improvement in shelf life is effected by applying hydrofluoric acid to packaging for the containment of the cyanoacrylate adhesive compositions in accordance with the present invention.
- the packaging may be in the form of any used for cyanoacrylates, typically including glass, metal, plastic and combinations thereof. As Example 15 below will serve to show, treatment of the packaging in this manner stabilizes the monomers, extending the period of time before complete polymerization occurs and thereby extending the shelf life of the compositions.
- a method for improving the plasticity of the resulting adhesive includes the addition of tocopherol acetate, or other esters of tocopherol.
- Tocopherol acetate, a form of vitamin E effects a more flexible cured product. This added benefit is particularly useful in medical adhesives where common movement contort body surfaces.
- the tocopherol additive may be incorporated into the cyanoacrylate adhesive composition in concentrations of approximately 5% to approximately 15% by weight.
- concentration of tocopherol ester added is approximately between 5% and 10% by weight to impart necessary or desirable flexibility to the product.
- esters of tocopherol to cyanoacrylate compositions in accordance with the present invention
- compounds of selenic acid or selenous acid may be added to cyanoacrylate adhesives to improve shelf life of the resulting cyanoacrylate adhesive.
- the selenic acid is preferably added in a concentration typical of acid stabilizers used in the art. Typically, the concentration used is approximately 10 ppm to several hundred ppm, but most preferably in the range of 20 ppm to 200 ppm.
- the selenic acid may be combined with other known stabilizers and antioxidants.
- cyanoacrylate adhesive By treating the cyanoacrylate adhesive in this manner stabilizing is effected by the use of entities exhibiting both acid functionality and phenolic structures in the same molecule.
- the cyanoacrylate adhesive may be further treated with prior art stabilizers.
- the following examples serve to demonstrate the advantageous increase in shelf life through the treatments described above.
- the first example demonstrates improved stability when using strong acids, in particular, hydrofluoric acid, in the treatment of packaging for containment of cyanoacrylates.
- the second example demonstrates improved plasticity in a like manner, as well as increased viscosity, through addition of tocopherol acetate.
- the final example exposes the effectiveness of the new class of dual functionality stabilizers disclosed above.
- Thymol blue and sulfur dioxide were blended into 2-octyl cyanoacrylate at 46 and 13 ppm, respectively.
- This composition was compared to one having 75 ppm sulfur dioxide and a third composition of 60 ppm sulfur dioxide and 46 ppm sulfuric acid. Heat ageing of the compositions resulted in a distinct visual difference in fluidity (no viscosity was determined).
- the fluidity was highest with the thymol composition and least with the sulfur dioxide/sulfuric acid system. This is particularly relevant as the thymol system has a total of 59 ppm acid versus the second with a total of 106 ppm acid.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Adhesives Or Adhesive Processes (AREA)
- Materials For Medical Uses (AREA)
- Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
Abstract
A new adhesive method using an adhesive composition including cyanoacrylate adhesive and a stabilizing agent to join together portions of a substrate, particularly useful in suturing and similar medical procedures, is disclosed. It is based on the discovery that remarkable improvements are obtained by adding a step of removing stabilizing agent from such adhesive compositions in the manufacturing process with the prior known steps of (a) providing an adhesive composition including cyanoacrylate adhesive and a stabilizing agent, (b) presenting a substrate to receive at least a portion of such cyanoacrylate adhesive and (c) applying such portion to the substrate. Devices for use in performing the method are described.
Description
- This application is a continuation of U.S. patent application Ser. No. 10/101,346, filed Mar. 20,2002, entitled “Method for Curing Cyanoacrylate Adhesive”, which is currently pending, which is a continuation-in-part of U.S. patent application Ser. No. 10/077,852, filed Feb. 20, 2002, entitled “Method for Curing Cyanoacrylate Adhesive”, which is abandoned.
- 1. Field of the Invention
- This invention relates broadly to a method of treating stabilized cyanoacrylate adhesives prior to their application to a substrate, particularly with reference to medical procedures using such adhesives.
- 2. Description of the Prior Art
- Medical interest in cyanoacrylate polymers has been apparent since at least the mid-nineteen sixties as evidenced by numerous reports on its use as a tissue bonding agent. Collins et al. reported on the effectiveness of homologous chain cyanoacrylates for bonding of biological substrates. J. A. Collins, et al., ARCH SURG. Vol. 93, 428 September 1966; F. Leonard et al., J.A.P.S. Vol. 10: 1617, 1966. Both articles report the observation of high rates of polymerization with longer chain esters than with the methyl or ethyl monomers. There appeared to be more biocompatability with the longer chains as noted by the ease of spreading monomer films on bio-substrates. This contrasted with in vitro polymerizations where the lower homologues reacted much faster. There was particular interest in the degradation of these polymers as they related to possible harmful effects that would preclude their use in surgery.
- Woodward et al. reported histotoxicity of these monomers in rat tissue. S. C. Woodward, et al., ANN. SURG. Vol. 162, July 1965. The study involved in situ polymerization of three cyanoacrylate monomers: methyl, hexyl, decyl. It was reported that histotoxic effects were greatest with methyl and decreased with the other two monomers.
- The same group reported on the use of radioactive methyl cyanoacrylate for monitoring routes for the loss of the polymer. J. J. Cameron et al., SURGERY, Vol. 58, August 1965; C. H. McKeever, U.S. Pat. No. 2,912,454, Nov. 10, 1950. Results indicated that the polymer was degraded and excreted principally through the urine and feces. Analysis of the animal's organs revealed no signs of radioactivity. This implied no degradation products were incorporated into any of the animal's metabolic pathways. By analogy to poly-vinylidene cyanide, they noted that the cyanoacrylate polymer degraded in the presence of water and more so in the presence of bases. The first observed degradation product turned out to be one of the starting materials, i.e., formaldehyde. In vitro studies have shown that the polymers degrade via hydrolytic scission in homogeneous as well as heterogeneous conditions. F. Leonard et al., J.A.P.S., Vol. 10: 259, 1966. These degradation products were confirmed to be formaldehyde and the corresponding cyanoacetate. The conditions of solution degradation affected the consequent rates, namely, under neutral conditions rates decreased as the homologous series was ascended while alkaline conditions increased all rates.
- The same study reported that the hydroxyl group was evident in the polymer as the initiating species. This was concluded from infrared spectral data that displayed hydroxyl group absorption at 3600 cm(−1). Further support for this is the noted suppression of the OH as water is replaced with methanol and the observed methoxy absorption at 1100 cm (−1). Preferential initiation was shown to occur with NH2 containing substances such as pyridine, cysteine, alanine, and glycine in aqueous solutions. This suggested that in vivo adhesion was more than a mechanical interlocking of the solid polymer with the tissue. This appears to be the case as it was noted that typical polymer solvents were not effective in solvating tissue-bound polymer.
- From this it appears that in vivo studies of degradation do not necessarily correspond to in -vitro conditions. Part of the degradation mechanism relies on the conditions of the polymer for hydrolytic scission. The chemical bonding of the polymer excludes this surface from hydrolytic activity. A mechanism of degradation was proposed that suggests an action similar to unzipping in acrylics, however, the difference being that the monomer is not regenerated. The proposed mechanism necessitates the presence of the hydroxyl as well as the presence of water.
- An unusual effect was reported regarding the aqueous degradation of isobutyl cyanoacrylate. R. H. Lehman et al., ARCH SURG. Vol. 93: 441, 1966. Of the monomers tested (methyl, propyl, butyl, isobutyl, heptyl, octyl), it was the only one that degraded more rapidly than any of the unbranched homologues, with the exception of the methyl monomer.
- A second study reported that in vivo experimentation gives credence to the chain scission mechanism by hydrolysis. M. Yonezawa et al., YUKI GOSEI KAGAKU KYOKAISHI, Vol. 25, 1967. When beta-(14) carbon tagged cyanoacrylate is implanted in rats, radioactive urea is isolated from urine. This suggests that tagged formaldehyde is released, converted to carbon dioxide and in turn reacts with ammonia to produce urea. F. Leonard, ADHES. BIOL. SYS. 1970.
- Rates of degradation on ethyl, butyl, and hexyl cyanoacrylates were evaluated with regards to molecular weights, concentrations, and side chain structures. W. R. Vezin et al., J. PHARM. PHARMACOL., Vol. 30, 1978, Suppl. The method employed buffered systems of pH ranges from 5.97 to 7.88. As expected, the rates increased with increasing pH. Scanning electron microscopy of the degraded polymer indicated that reaction occurs at the surfaces and not internally through diffusion. It was postulated that the greater the length of the—alkyl side chain, the more protection provided to the labile hydroxyl end of the polymer chain. This in turn would provide greater resistance to degradation of the polymer. Degradation rates do in fact correspond to chain length protection. The relative rates of degradation for hexyl, butyl, and ethyl were, respectively, 1.0, 1.36, 9.55.
- The same group reported on a study whereby degradation rates were retarded by increasing the chain length of the polymer. W. R. Vezin et al., J. BIOMED. MAT. RES., Vol. 93, 1980. Very small quantities of impurities in the monomers had a significant impact on the final outcome of the degree of polymerization. Further to this study, within the ethoxyethyl system, longer chain length enhanced the degradation resistance of the resultant polymer.
- A comparative study of ethyl cyanoacrylate and polyurethane in-situ generated adhesives and coatings was reported in U.S. Pat. No. 4,057,535 to Lipatova et al. The study claimed the superiority of the polyurethane structure due to high flexibility and compatibility with the treated tissues. The single comparison was made with incised tissue and consequent application between the wound edges. Inferiority of this application for the cyanoacrylate was readily evident, but true topical applications were not compared. Of eleven examples given, four were of a topical method, yet no data was presented as no application of the ethyl or any other homologue was done conjunctively for comparative efficacy. A further deficiency of this patent is the practicality of use. No indication is given for a device to properly apply the two part system and appears to indicate an at-site preparation.
- Another patent, U.S. Pat. No. 5,192,536 to Robinson overcomes the issue of the apparent difficulties associated with the invention disclosed in U.S. Pat. No. 4,057,535 by taking preformed polyurethane and dissolving it in a rapidly evaporating solvent such as tetrahydrofuran. The composition is designed to form a “membrane-like cover over the wound” and “assists in maintaining closure of the wound”. Again no comparative studies were reported.
- U.S. Pat. No. 3,995,641 to Kronenthal et al. discusses the novelty of modified cyanoacrylates, namely, carbalkoxyalkyl cyanoacrylates. The patent discloses their usefulness as a tissue adhesive in surgical applications. The presumed superiority of these products was attributable to the rapid hydrolytic decay and concurrent low degree of histotoxicity. Since no data is presented regarding formaldehyde evolution, it is presumed that the hydrolysis mechanism does not scission the polymer to generate it.
- U.S. Pat. No. 5,254,132 to Bartley et al. discloses the use of a hybrid method of surgical application of cyanoacrylates. It discloses a combination of sutures and adhesive such as to be mutually isolated from each other, but to both support the re-growth of the tissue in the wound area. The '132 patent addresses the issue of insuring no contact of adhesive in the suture area so as to assure no inclusions of the cyanoacrylate. The disclosed method appears to be awkward and cumbersome, and requires a very effective and controlled dispensing of the adhesive without contacting the suture. Additional concern is indicated as a suggestion is made to employ a solvent (acetone) if any surgical instrument happens to be bonded inadvertently to the treated area.
- U.S. Pat. No. 5,328,687 to Leung et al. attacks the formaldehyde issue by incorporating a formaldehyde scavenger, such as, sodium bisulfite. The various compositions were evaluated via in-vitro experimentation. The examples presented all had a presumably excessive level of scavenger. The representative compositions had loadings of 20% of a scavenging agent that was designed to offset formaldehyde emissions that were at 0.1%. As indicated previously, in-vitro and in vivo conditions are not identical and certainly not in this instance. The in-vitro conditions presented in the '687 patent do not factor in the dynamic conditions in living tissue. The surgically treated area would be under continuous and changing fluids as the organ attempts to bring in the necessary biocomponents to heal the traumatized tissue. As such, it would not be expected that the scavenger/formaldehyde ratio would be maintained as it was in the in-vitro state. It could be speculated that the use of such high loadings of any fluid solubilized additives would contribute to greater formaldehyde emissions. This can be assumed to be a consequence of dissolution of the additives resulting in cavities in the polymer, thereby promoting greater surface area for hydrolytic degradation.
- U.S. Pat. No. 5,403,591 to Tighe et al. relates to the use of cyanoacrylates for treatment of skin irritations that progress to ulcerations. It would be assumed that these conditions could be considered wound formations, e.g., see U.S. Pat. No. 3,995,641.
- U.S. Pat. Nos. 5,928,611 to Leung, 5,981,621 to Clark et al., 6,099,807 to Leung, 6,217,603 to Clark et al. describe methods of inducing cure of cyanoacrylates bypassing the adhesive through a porous applicator tip containing substances that initiate the polymerization. These substances co-elute and dissolve into the adhesive as it is forced through the porous tip.
- U.S. Pat. No. 6,143,352 to Clark et al. describes methods of altering the pH environment of cyanoacrylates in order to attenuate or accelerate the rate of hydrolytic degradation by uses of acid and alkaline additives. The formulation of acidic modifiers is problematic as they tend to inhibit the primary characteristic of these materials, namely, rapid cure on application to tissue. Data is presented on effects of acidic compositions on previously cured cyanoacrylates, not on in situ applied compositions.
- All of these methods rely on the addition of various compositions to affect the accelerated cure onto a desired substrate. These compositions may induce polymerization by creating a greater number of initiation sites and or orientation of the monomer for more facile polymerizations. Other plausible mechanisms can be evoked, but the fact remains that the added materials become a part of the composition (undesirable for many medical applications). As such, these chemical inclusions may elicit unfavorable reactions in the cured state. In particular, the use of pH-based accelerators may contribute to the alkaline hydrolysis of the cyanoacrylate polymer.
- This is particularly undesirable in medical applications of the cyanoacrylates as the hydrolysis results in the evolution of formaldehyde. A certain level of formaldehyde can be tolerated by tissue as it is able to dispose of reasonable concentrations. A solution proposed in the prior art has been increasing the chain length of the cyanoacrylate monomer side group; in particular, that it be alkyl so as to impart hydrophobic character to the resulting polymer.
- The prior art methods and compositions have been able to achieve a synthesis of the octyl cyanoacrylate at economic levels for applications in the medical field, although improbable for uses in commercial applications due to reaction yields. A number of methods have been attempted to improve yields. Yin-Chaos Tseng et al., BIOMATERIALS, Vol 11, 1990. The variables looked at included: azeotropes, temperature and formaldehyde/cyanoacetate ratio. Other methods have also included assessment of different catalysts for the condensation reaction. Regardless of the methods tried, yields become increasingly smaller as the cyanoacetate pendant group becomes larger.
- An attempt to improve yields is reported in U.S. Pat. No. 6,245,933 to Malofsky. This method attempts to avoid yield losses by producing the high yield cyanoacrylate prepolymers of the lower homologues (methyl & ethyl) and then proceed through a transesterification with a longer chain alcohol such as the octyl. Three reported examples with 2-octanol gave yields ranging from 21.8% to 36.2% of crude monomer.
- From this, it can be seen that high yields are difficult and no doubt subsequent work-up to medically acceptable products result in even lower product output. The difficulty with methods such as discussed above, is the undesirable side products that are difficult to remove from the main stream. In particular, it is difficult to achieve complete transesterification reactions on polymeric moieties because of steric obstruction. As a consequence, purity is compromised as the initial cyanoacrylate prepolymer is not completely reacted and the lower homologue co-distills with the desired product.
- Other additives have been used to attenuate various properties, such as modulus (elasticity, viscosity, thermal resistance, etc. Each and every additive becomes a substance that must be removed by the surrounding tissue, which generally does not assist in recovery of the damaged area. In that regard, the addition of these additives must weigh the effect of property improvements against the effect on tissue compatibility.
- In contrast to additives for the cured adhesives are additives formulated into the synthesized monomers. The synthetic route for monomer production relies on two principal groups of stabilizers. The first group is chosen from substances capable of preventing free radical polymerization and the second group inhibits the anionic polymerization.
- The critical step in the production of these monomers relies on the high temperature thermal degradation of the polymer generated from the formaldehyde-cyanoacetate reaction. These temperatures span the range of 150° C. to excesses of 200° C. Under ideal conditions, this polymer will undergo a clean unzipping reaction that releases the cyanoacrylate monomer. This begins to take place in the lower temperature regions and must be gradually elevated to extract the increasingly difficult boiling off of the monomer. Elevation of the temperature is necessary as byproducts form and increasingly hamper the volatilization of the desired monomer.
- In order to prevent the thermal reversal of the monomer back to polymer as it is generated and exits the body of fluid polymer in the reaction vessel, retarders or inhibitors are added at the beginning of this process. These substances react with free radicals to form a stable unreactive species, thereby halting the thermal polymerization typical of vinyl monomers. Quinones are the most often used substances in this group. Typical, but not exclusive, are hydroquinone and methyl ether hydroquinone. The presence of these additives is most critical in the monomer-polymer mix in the reaction vessel. Once the monomer is vaporized, it is quickly cooled to ambient conditions as it is distilled over to a suitable receiver.
- The second group of stabilizers are used to prevent the anionic polymerization of the monomer in the reaction vessel as well as the vapor and collected liquid monomer in the receiver. Those knowledgeable in the art are quite familiar with these substances. Typical, and again, not exclusive, are the sulfonic acids and sulfur dioxide. In general, acidic substances are chosen to effect stabilization not only during the production of these monomers but further for stabilization during storage.
- A fine line exists in the levels of these anionic stabilizers. If there is insufficient loading of these acids during the polymer unzipping to monomer, the vaporized and condensing monomer will begin to repolymerize throughout the system. On the other hand, if too much anionic stabilizing takes place in the distilled monomer, the desired repolymerization is not easily accomplished. This is evidenced by those patents cited above that deal with the loading of alkaline substances and other anion polymer promoting initiators in a porous tip. These additives are necessary to overcome the excessive levels of anionic stabilizers that co-distill during the distillation of monomer.
- In the manufacture of the lower homologues such as the methyl, ethyl, and butyl monomers, the degradation of the polymer to monomer is much more effective and gentle, requiring lower levels of these anionic stabilizers. The resultant distilled monomers are thereby stabilized sufficiently and in some cases additional acid is charged, usually under 100 parts per million, to effect a useful shelf life for commercial applications.
- These lower homologues are, as are all of the cyanoacrylates (with some exceptions such as the difunctional ones), distilled under vacuum conditions. The typical vacuum is in the 0.5 mm H to 2.0 mm Hg. As the molecular weight of these monomers increases, the required vacuum conditions become more critical. In order to effectively distill the higher molecular weights, the vacuum conditions must continue beyond the range of approximately 0.5 mm Hg. Higher distillation temperatures with poor vacuum conditions results in increasing levels of undesirable byproducts, and consequent poor yields and inferior product.
- As a typical example, it is necessary to achieve a vacuum in the range of approximately 0.01 mm Hg to 0.05 mm Hg for the octyl monomer and higher homologues in order to effectively distill the monomers in a nondestructive process. This, however, is the crux of the problem in the isolation of these monomers as confronted in the prior art methods and systems.
- The lower homologues and typical anionic stabilizers have a sufficiently large difference in their respective boiling points, such that very little stabilizer is co-distilled with the monomer. This, however, becomes an increasingly important issue as the vacuum levels proceed to better distill over the higher boiling monomers like the octyl, decyl and so on. The consequence then is that increasing levels of the stabilzer co-distill along with the desired monomer. The resultant isolated monomer is excessively loaded with anionic stabilizer(s) thus requiring the devices referred to above.
- In addition, and as generally discussed above, prior art methods for the synthesis of cyanoacrylate monomers generally require the addition of acids and free radical inhibitors during the monomer synthesis. The free radical inhibitors prevent premature polymerization during the thermal unzipping reaction as well as the follow-up distillation step(s). The acid additives are necessary to prevent premature polymerization during workup and storage of these compositions. However, and as discussed above, as the chain lengths become increasingly longer, higher temperatures are necessary to effect the unzipping reaction. A direct unintended result is that excessive levels of acid are necessary with the consequent overstabilization of the distilled product.
- It, therefore, becomes necessary to negate this overstabilization in order to facilitate the anionic polymerization. To date, all means of effecting this have been by pretreatment of the substrate with, for example, alkaline and/or organic soluble amines that are intended to initiate the anionic polymerization by dissolution into the adhesive. Though not specifically stated, this approach is apparently based on the view that as the mass of the side chain group increases, the polymerizability drops off. This is apparent, as all current techniques rely on overriding the excess stabilizer levels. Alternative methods employ a solution of these initiators being sprayed over the adhesive after it has been applied to the substrate. The other variant of this soluble initiator method are those referenced above incorporating the initiator in the porous applicator tip. As those skilled in the art certainly appreciate, neither of these approaches is desirable for medical procedures.
- With the foregoing in mind, a need currently exists for a method by which cyanoacrylate adhesives may be rapidly cured without contaminants or extraneous additive. The present invention provides such a method.
- It is, therefore, an object of the present invention to provide a method for increasing the shelf life of a cyanoacrylate adhesive by increasing the stability of the adhesive. The method includes treating packaging for containment of the cyanoacrylate adhesive or precursors to the cyanoacrylate adhesive with a strong acid. The cyanoacrylate adhesive or precursor to the cyanoacrylate adhesive is then introduced to the packaging.
- It is also an object of the present invention to provide a method wherein the strong acid is hydrofluoric acid.
- It is another object of the present invention to provide a method for increasing the shelf life of a cyanoacrylate adhesive including the step of treating the cyanoacrylate adhesive with a stabilizing compound.
- It is a further object of the present invention to provide a method for increasing the shelf life of a cyanoacrylate adhesive including the step of treating the cyanoacrylate adhesive with at least one acid stabilizing compound of selenic or selenous acids.
- It is still another object of the present invention to provide a method of plasticization of a cured polymer with an ester of tocopheral, and more particularly, tocopherol acetate.
- It is also an object of the present invention to provide a method wherein the ester of tocopherol has a concentration in the range of approximately 5% to approximately 15% by weight.
- It is another object of the present invention to provide a method for increasing the shelf life of a cyanoacrylate adhesive including the step of treating the cyanoacrylate adhesive with selenic acid.
- It is still another object of the present invention to provide a method for increasing the shelf life of a cyanoacrylate adhesive. The method is achieved by treating the cyanoacrylate adhesive with structures functionalized with both free radical and anionic inhibition in the same molecule. Typical, but not exclusive, the treating compounds are titration indicators, also referred to as acid-base indicators. The levels of limitations are defined as sufficient to provide practical shelf life as well as acceptable utility in cyanoacrylate applications.
- Other objects and further scope of applicability of the present invention will become apparent from the detailed descriptions given herein; it should be understood, however, that the detailed descriptions, while indicating preferred embodiments of the invention, are given byway of illustration only, since various changes and modifications within the spirit and scope of the invention will become apparent to those skilled in the art from such descriptions.
- The detailed embodiments of the present invention are disclosed herein. It should be understood, however, that the disclosed embodiments are merely exemplary of the invention, which maybe embodied in various forms. Therefore, the details disclosed herein are not to be interpreted as limited, but merely as the basis for the claims and as a basis for teaching one skilled in the art how to make and/or use the invention.
- As discussed above, the present invention generally relates to a method for curing reactive monomeric cyanoacrylates to undergo macromolecular formations via appropriate modification of anionic stabilizer levels in a manner permitting utilization of the resulting adhesives in the treatment of human, or animal, tissue and/or flesh, required to be otherwise sealed or sutured, or otherwise protected from its surroundings. While certain distinctions may be drawn between the usage of the terms “flesh” and “tissue” within the scientific community, the terms are used herein interchangeably as referring to a general substrate upon which those skilled in the art would understand the present adhesive to be utilized within the medical field for the treatment of patients. Without being bound to a specific mechanism, such modification of the anionic stabilzer levels chemically and/or physically removes stabilizing agents so the present method allows for reformulation of compositions capable of reasonable cure speeds without external anionic initiators.
- The present method generally includes the steps of providing a long shelf life stable adhesive composition comprising cyanoacrylate adhesive and excess stabilizing agent(s), removing excess stabilizing agent(s) from the adhesive composition, re-stabilizing and presenting a substrate to receive at least a portion of the cyanoacrylate adhesive composition and applying the cyanoacrylate adhesive portion to the substrate.
- Cyanoacrylate adhesives that may be used in accordance with the present invention, comprise one or more monomers having the following general structure:
- CH2=(CN)—C(O)—R
- Without encumbering the body of this patent with specific examples of moieties, reference is made to the numerous patents delineating the myriad of groups that can be represented by the moiety designated as R, many representative examples being given in the cited references. With this in mind, these, as well as other moieties, may be employed without departing from the spirit of the present invention. In the case of difunctional cyanoacrylates, R would be bound to two reactive groups. These are, therefore, intended to define and be included by general reference to such prior art and by those knowledgeable thereof.
- As discussed above in the Background of the Invention, the various methods for the synthesis of these monomers generally require the addition of acids and free radical inhibitors during the monomer synthesis. The free radical inhibitors prevent premature polymerization during the thermal unzipping reaction as well as the follow-up distillation step(s). The acid additives are necessary to prevent premature polymerization during work-up and storage of these compositions.
- However, as the chain lengths become increasingly longer, higher temperatures are necessary to effect the unzipping reaction. A direct unintended result is that excessive levels of acid are necessary with the consequent overstabilization of the distilled product. It, therefore, becomes necessary to negate this overstabilization in order to facilitate anionic polymerization of the adhesive composition.
- Prior art techniques rely upon pretreatment of the substrate with, for example, alkaline and/or organic soluble amines that are intended to initiate the anionic polymerization by dissolution into the adhesive. This approach is apparently based on the view that as the mass of the side chain group increases, the polymerizability drops off. This is apparent, as all current techniques rely on overriding the excess stabilizer levels. Alternative prior art methods employ a solution of these initiators being sprayed over the adhesive after it has been applied to the substrate. The other variant of this soluble initiator method are those referenced above incorporating the initiator in the porous applicator tip.
- Since the difficulty in polymerization of these longer chain moieties is due to excessive acid levels, in accordance with the present invention the acids are removed rather than neutralized. As noted above, polymerization is achieved by the addition of initiators to overcome the stabilizing effects of these acids and so remain in the resultant polymer matrix. The concept of acid removal is also the focus of a co-pending U.S. patent application Ser. No. 09/982,226, filed Dec. 19, 2001, which is incorporated herein by reference. The '226 application describes the use of acid removing particulates during the coincidental application of these adhesives. The utility of this method is limited by a period of time in which the adhesive can be applied. It would be most desirable to have a greater degree of freedom in time to apply these adhesives.
- This present method achieves this goal by removing stabilizers in cyanoacrylate adhesives prior to their application to substrates. This renders the resultant purified compositions highly susceptible to polymerizations when applied to the substrates. Again, without being bound to any single specific mechanism, this process relies on a combination of physical adsorption/absorption, chemical reaction, and hydrogen bonding of the acid group(s) onto particulate surfaces. It is necessary to have the acid removing particulate substances, in fluid contact with the excessively stabilized monomer(s), be insoluble or otherwise isolatable from the monomers, such as by filtration, centrifugation, phasing out, membrane separation, or other appropriate isolating mechanism. The requisite is the isolation of the acids or other stabilizers from the monomers.
- Substances exhibiting these mechanisms encompass polymers capable of forming hydrogen bonds with the stabilizing acids. These polymeric materials can have carbonyl, hydroxyl, amide, carboxylic, amine, ether, anhydride, ester, urethane, sulfone or other structures or combination structures capable of coupling or otherwise fixing the acid stabilizer to the isolatable substances. These polymeric materials can also be inorganic such as silicates. Other contemplated particulates are those in which the stabilizers are selectively trapped in zeolytic substances or otherwise caged in molecular sieves.
- Chemical isolation can be achieved by, for example, reactive contact with anhydride structures such as on copolymers containing maleic anhydride. It is postulated that the anhydride structure reacts to form an anhydride link with the mobile (stabilizing) acid and a carboxylic group, both being bound to the polymer chain; an example for this being maleic anhydride copolymers of styrene and ethylene.
- Physical removal of the excess stabilizers may be accomplished by such substances as activated carbon, which appears to rely on adsorption of the stabilizer(s) as a result of the high surface area and polar surface structures.
- These mechanisms of treatment are not meant to be mutually exclusive, but can, in fact, be acting by any and all combinations to remove the excessive stabilizers. A typical example is the use of activated carbon, which has oxidation structures that are likely to participate in hydrogen bonding as well as physical adsorption. A further example is the use of more than one substance, such as polymer(s) and inorganic(s) in a single treatment or sequential or multiple treatments.
- To most effectively use stabilized cyanoacrylate adhesives for medical applications in accordance with the invention, they are stored in a device that houses a crushable ampoule containing such adhesives. Such ampoule containing devices may be constructed of any number of materials that can be shaped or molded or otherwise fabricated to contain the adhesive and ampoule. The application devices are preferably manufactured from such materials as to effect a resilient wall capable of transmitting pressure to the crushable ampoule without loss of its containment properties. These application devices advantageously further comprise a filtering component and nozzle for application of the filtered adhesive to the substrate, for example, tissue of the patient being treated. Examples of application devices which may be used in accordance with the present method are disclosed in detail in the '226 application which, as discussed above, is incorporated herein by reference.
- The application devices can also be designed to apply the product in a continuous manner. An example of such a device is one that incorporates a reservoir of the appropriate adhesive feeding through a valving mechanism, thereby providing a source of adhesive without an ampoule.
- In multi-application uses the properly treated cyanoacrylate is contained in appropriate vessels such as glass or high-density polyethylene. These containers may be pretreated so as to effect useful shelf life. Reference again is made to those familiar with the art and patents delineating the various methods to achieve this treatment. Typically a container would hold 2-5 grams of product to provide many topical applications with appropriate disposable applicators such as pipettes.
- In a preferred embodiment, one of the above described devices houses 2-octyl cyanoacrylate which has been previously treated with poly(vinyl pyrrolidone/vinyl acetate) copolymer. The ampoule is crushed and the contents are then expressed through the appropriate filter and dispenser tip onto the substrate, specifically human, or animal tissue, or skin. The application is accomplished in such fashion as to prevent encapsulation of adhesive by any surrounding tissue. Though ultimately these inclusions are degraded and excreted, it is most desirable to minimize this occurrence to maximize reconstitution of the surrounding tissue. The need to assure this minimization was noted in U.S. Pat. No. 3,667,472 which pointed out the requisite to bridge the wound without diffusing into it. This was accomplished by bringing the wound edges together followed by application so as to effect a bridging over the wound to circumvent necrosis and irritation by this technique.
- A second preferred embodiment utilizes the above-described devices containing decyl cyanoacrylate.
- A third preferred embodiment utilizes the above-described devices containing dodecyl cyanoacrylate.
- A fourth preferred embodiment includes the above with combinations of cyanoacrylate monomers to achieve control over the rate of hydrolytic degradation so as to improve compatibility with tissue by control of formaldehyde emissions.
- In accordance with a preferred embodiment, the invention employs vinyl pyrrolidone polymers and copolymers to remove stabilizers from the cyanoacrylate adhesives formulation. These particulate agents are combined with the monomer adhesive in mutual contact until the adhesive is destabilized, whereupon the adhesive becomes isolated from the destabilizing agent by various means such as to effect isolation of the adhesive from the destabilizing component. Once isolated, the adhesive is restabilized at reduced levels so as to effect timely cure rates in the 5 seconds to approximately one minute range. It should further be understood that these particulate agents may have some degree of solubility and therefore may pass through along with the adhesive onto the substrate. It is only a requisite that enough excess stabilizer is left behind so as to provide the desirable speed of cure. It should also be understood that re-stabilization is also desirable in order to provide a balance between speed of cure and shelf life. It should be further understood that oligomeric or low molecular weight fractions may indeed be somewhat soluble in the cyanoacrylate adhesives but still be effective in producing a desirable adhesive composition.
- A novel improvement in shelf life of these adhesives has been observed with the use of stabilizers having both phenolic and acidic functionalities in the same structure. These types of substances are typically recognized as acid-base indicators or titration indicators. The following compounds are contemplated for use in accordance with a preferred embodiment of the present invention: thymol blue, trisulphonated napthol, phenolsulfonapthalein, pyrochatechol violet, acid yellow, bromophenol blue, phenol red, and cresol red. An additional benefit is the inherent color imparted to some of the compositions utilizing the stabilizers. These can serve as visual indicators of coverage on the substrate. The concentrations of these dual function stabilizers are expected to be effective in ranges typically associated with sulfur dioxide, sulfonic acids, and other acids as well as in the ranges associated with the phenolic stabilizers for these monomers as is known in the art. They may further act synergistically with stabilizers of the prior art.
- Advantageously, the device of the invention is one that (a) delivers the cyanoacrylate adhesive of convenient viscosity, (b) contains a porous segment for the containment of the ampoule and other components so as to permit the release of the adhesive with no particulate components being released onto the substrate to which it is applied, (c) delivers the adhesive through a nozzle applicator tip configured for appropriate application onto the substrate, and (d) can be used with other monomer formulations prior to application to effect the desired result such as polymerizations to produce various thermoplastic and thermoset resins of both organic and inorganic nature.
- All of preferred embodiments disclosed in accordance with the present invention should be understood to further include all of the various additives useful in the alteration and improvement to cyanoacrylate adhesives as would make them suitable for placement into the above devices, substrates, and modifications to these and similar devices. These can include plasticizers, stabilizers, surface insensitive additives, tougheners, thickeners, adhesion promoters, other monomers, comonomers, and other such compositions as would be evident to those familiar with the cyanoacrylate adhesives art.
- The following preferred examples further disclose the new method and display its effectiveness.
- A quantity of particulate destabilizing agent (5 grams) in the form of vinyl pyrrolidone vinyl acetate copolymer is blended with (25 grams) 2-octyl cyanoacrylate for a period of 24 hours. The resultant slurry is filtered to effectively remove the destabilizing agent and is restabilzed at a level to achieve the desired cure speed for the following test. In particular, 6 grams of the treated monomer is blended with 0.012 grams of pretreated monomer. A glass ampoule is charged with 0.5 grams of treated monomer and sealed with a gas flame. The ampoule is inserted into a tubular device referred to as a Tandem Dropper supplied by James Alexander Company of Blairstown, N.J., that also provided unsealed ampoules. In order to filter matter dispensed from the dispenser tip of the Tandem Dropper, it is plugged internally with a small wad of polyester fiber also supplied by James Alexander Company. The dispenser tip press fits onto the end of the Tandem Dropper after insertion of the sealed ampoule.
- The assembled device is squeezed to effect rupture of the ampoule. Pressure is applied so as to exude a drop of adhesive through the filtering tip. The drop is applied to skin and timed to determine when the film has undergone cure to a non-tacky surface. The 2-octyl cyanoacrylate undergoes cure in 10-20 seconds upon application to skin on the back of the hand. This contrasts with untreated 2-octyl cyanoacrylate which shows no sign of cure up to 3 minutes whereupon the test is terminated.
- A 10 milliliter glass vial is charged with 0.5 grams of activated charcoal Calgon WPX, sourced from Calgon Carbon Corp. of Pittsburgh Pa. Followed by this is a 6.0 gram charge of 2-octyl cyanoacrylate which is mixed for a period of 30 minutes. The resulting dispersion is filtered to isolate the cyanoacylate into a small ampoule. A test of cure speed on skin of the isolated monomer results in the formation of a protective film in 10 to 20 seconds in a manner similar to example 1 above.
- A 3 milliliter test tube is charged with 0.016 grams of anhydrous potassium carbonate and 2.030 grams of 2-octyl cyanoacrylate which is then sealed and shaken for approximately 2 hours. It is stored for 17 days. A sample is removed and applied to the skin with a consequent film cure in a range of 110 to 120 seconds.
- Example 3 is repeated with a higher loading of the anhydrous carbonate: 0.27 grams and 2.46 grams of 2-octyl cyanoacrylate. The test tube is stored for 15 days whereupon a test of cure exhibits film formation in 120 seconds.
- A 50 milliliter flask is charged and sealed with 1.5 grams of polyvinyl alcohol granules (BP-05) and 18.5 grams of 2-octyl cyanoacrylate. The dispersion is intermittently shaken for a period of 48 hours due to the more coarse nature of the polymer. A sample is taken and tested on skin to show a cure of film in 90 to 100 seconds.
- A flask is charged and sealed with 1.0 grams of ethylene-vinyl acetate copolymer RP251 (Wacker Polysystems) and 18.5 grams of 2-octyl cyanaocrylate. The dispersion is intermittently shaken for 48 hours prior to the skin test. Upon testing the treated monomer cured in approximately 100 seconds
- Example 6 is repeated with RP140, a vinyl acetate homopolymer. The resultant treated monomer gave a cure after 130 seconds.
- A 10 milliliter flask is charged and sealed with 1.0 grams of poly(methyl methacrylate) (Rhohadon M449, Rohmtech Inc.) and 6 grams of 2-octyl cyanaocrylate. After intermittent shaking for 24 hours, the dispersion is filtered and the isolated monomer is tested to reveal a film formation in 30 to 35 seconds.
- A 10 milliliter flask is charged and sealed with 1.0 grams of styrene-maleic anhydride copolymer (SMA-3000, Atochem Inc.) and 6 grams of 2-octyl cyanoacrylate. Subsequent isolation of the monomer after 24 hours of treatment gave a cured film on skin in approximately 65 seconds.
- A 10 milliliter flask is charged and sealed with 0.5 grams of zinc oxide (AZO66, US Zinc Products Inc.) and 6 grams of 2-octyl cyanoacrylate. After shaking the dispersion for 30 minutes, subsequent filtration and testing on skin gave a cure in 50 to 60 seconds.
- A 10 milliliter flask is charged and sealed with 0.5 grams of “Hydrosource” (1-2 mm average diameter particles) polyacrylamide (Castle International) and 6.0 grams of 2-octyl cyanoacrylate. Subsequent testing after 4 hours of mixing gave a 30 second cure on skin.
- A 10 milliliter flask is charged and sealed with 1.6 grams of glass spheres (Class 4A size 203 from Cataphote Corp.) and 4.4 grams of 2-octyl cyanoacrylate. The mix was shaken for 2 hours prior to testing. The sampled droplet was spread on skin giving a 60 second cure.
- A 10 milliliter flask is charged and sealed with 1.6 grams of pulverized polyimide resin (Dupont Kapton 700HPP-ST film) and 4.4 grams of 2-octyl cyanoacrylate. The mix was shaken overnight prior to testing. An isolated sample gave a skin surface cure of 120 seconds.
- A two ounce, opaque polyethylene bottle is charged with 0.57 grams of vinyl pyrrolidone vinyl acetate copolymer and 30 grams of 2-octyl cyanoacrylate. The container is shaken for five minutes and stored for 3 months. A sample was taken and passed through a 0.2 micron filter with a 1 milliliter syringe. Application onto skin gave a very rapid cure of 10-15 seconds with noticeable warmth due to the more rapid polymerization.
- As evidenced by the last example, these additives can be left in contact with the cyanoacrylate with no apparent detriment to the shelf life and cure of the final product. It is further evident that these products can be kept without the need to isolate and store in glass ampoules. This further leads to the capability of large reservoirs of product to be dispensable through a disposable fibrous or porous tip. This is particularly advantageous in procedures where quantities necessary exceed the capacity of the crushable ampoules. The only limitations to the various treatments is the ability to isolate a practical level of cyanoacrylate monomer, i.e., that concentrations even at levels creating slurries can be filtered off to achieve economic quantities. These examples serve to show the extensive applicability of the primary requisite: to remove excessive stabilizer(s). No other references have addressed this issue, as those knowledgeable in the science and art of this technology have always understood the need to add, not remove, these stabilizing substances. It has not previously been recognized that the synthesis and isolation of these long chain side group cyanoacrylates results in excessive levels of these stabilizers. The preceding examples are intended to show the various types of cyanoacrylate insoluble materials that can perform the extraction of stabilizers. They are therefore intended to exemplify, not define the limits, of applicable substances.
- As those skilled in the art will certainly appreciate, a method and composition enhancing shelf life and stability would be highly advantageous, particularly for use with cyanoacrylate-based adhesives used in medical procedures. It has been found that the cyanoacrylate adhesive produced through implementation of the present invention, as well as their precursors, exhibit greater shelf life stability when subjected to treatment with strong acids. The treatment described herein may be employed alone or in combination with other known antioxidants and/or stabilizers typically used with cyanoacrylates.
- In accordance with a preferred embodiment, hydrofluoric acid is used to improve the shelf life of cyanoacrylate adhesives, as well as their precursors, produced in accordance with the present invention. The improvement in shelf life is effected by applying hydrofluoric acid to packaging for the containment of the cyanoacrylate adhesive compositions in accordance with the present invention. The packaging may be in the form of any used for cyanoacrylates, typically including glass, metal, plastic and combinations thereof. As Example 15 below will serve to show, treatment of the packaging in this manner stabilizes the monomers, extending the period of time before complete polymerization occurs and thereby extending the shelf life of the compositions.
- A method for improving the plasticity of the resulting adhesive includes the addition of tocopherol acetate, or other esters of tocopherol. Tocopherol acetate, a form of vitamin E, effects a more flexible cured product. This added benefit is particularly useful in medical adhesives where common movement contort body surfaces.
- The tocopherol additive may be incorporated into the cyanoacrylate adhesive composition in concentrations of approximately 5% to approximately 15% by weight. In accordance with a preferred embodiment, the concentration of tocopherol ester added is approximately between 5% and 10% by weight to impart necessary or desirable flexibility to the product.
- Further to the application of esters of tocopherol to cyanoacrylate compositions in accordance with the present invention, compounds of selenic acid or selenous acid may be added to cyanoacrylate adhesives to improve shelf life of the resulting cyanoacrylate adhesive. Those skilled in the art will appreciate other strong acids that may be utilized without departing from the spirit of the present invention. The selenic acid is preferably added in a concentration typical of acid stabilizers used in the art. Typically, the concentration used is approximately 10 ppm to several hundred ppm, but most preferably in the range of 20 ppm to 200 ppm. In addition, the selenic acid may be combined with other known stabilizers and antioxidants.
- By treating the cyanoacrylate adhesive in this manner stabilizing is effected by the use of entities exhibiting both acid functionality and phenolic structures in the same molecule. The cyanoacrylate adhesive may be further treated with prior art stabilizers.
- While the packaging treatments, tocopherol acetate treatments, selenic acid treatments and phenolic free radical stabilizer(s) treatments are employed with cyanoacrylate compositions as previously described in accordance with the present invention, it is contemplated these treatment methods may be employed with other cyanoacrylates without departing from the spirit of the present invention.
- The following examples serve to demonstrate the advantageous increase in shelf life through the treatments described above. The first example demonstrates improved stability when using strong acids, in particular, hydrofluoric acid, in the treatment of packaging for containment of cyanoacrylates. The second example demonstrates improved plasticity in a like manner, as well as increased viscosity, through addition of tocopherol acetate. The final example exposes the effectiveness of the new class of dual functionality stabilizers disclosed above. These examples are intended to illustrate the invention without, however, limiting the scope thereof.
- Glass ampoules suitable for containment of cyanoacrylate polymers in accordance with the present invention were treated with hydrofluoric acid at a concentration of 6.75% for a period of 5 minutes. The ampoules were then rinsed prying to drying in an oven at 120° C. A series of untreated ampoules were added to the collection as controls. Each ampoule, treated and untreated, was then loaded with 0.5 cc of treated octyl cyanoacrylate and heat sealed. The ampoules then underwent sterilization at 160° C. for 60 minutes followed by an ageing period at 95° C. A viscosity check was performed after 4 days. The untreated ampoules contained completely polymerized compositions. Those ampoules treated with hydrofluoric acid each recorded a viscosity of 52 cPs.
- Selenic acid and tocopherol acetate, respectively at 29 ppm and 5% in octyl cyanoacrylate in accordance with the present invention, was aged in glass ampoules treated as described above with reference to Example 15. A viscosity check following 4 days of storage revealed untreated ampoules containing a product having a viscosity of 298 cPs and treated ampoules containing a fluid product of indeterminate viscosity exhibiting softness when touched. The results indicate use of both an antioxidant/stabilizer in combination with tocopherol acetate provides a more compliant film as subjectively observed in comparison with comparable compositions from the first group of examples above.
- Thymol blue and sulfur dioxide were blended into 2-octyl cyanoacrylate at 46 and 13 ppm, respectively. This composition was compared to one having 75 ppm sulfur dioxide and a third composition of 60 ppm sulfur dioxide and 46 ppm sulfuric acid. Heat ageing of the compositions resulted in a distinct visual difference in fluidity (no viscosity was determined). The fluidity was highest with the thymol composition and least with the sulfur dioxide/sulfuric acid system. This is particularly relevant as the thymol system has a total of 59 ppm acid versus the second with a total of 106 ppm acid.
- While the preferred embodiments have been shown and described, it will be understood that there is no intent to limit the invention by such disclosure, but rather, is intended to cover all modifications and alternate constructions falling within the spirit and scope of the invention as defined in the appended claims.
Claims (12)
1. A method for increasing the shelf life of a cyanoacrylate adhesive by increasing the stability of the adhesive, the method comprising the following steps:
treating packaging for containment of the cyanoacrylate adhesive or precursors to the cyanoacrylate adhesive with a strong acid; and
introducing the cyanoacrylate adhesive or precursors to the cyanoacrylate adhesive to the packaging.
2. The method according to claim 1 , wherein the strong acid is hydrofluoric acid.
3. The method according to claim 1 , further including the step of treating the cyanoacrylate adhesive with a stabilizing compound.
4. The method according to claim 1 , further including the step of treating the cyanoacrylate adhesive with an ester of tocopherol.
5. The method according to claim 4 , wherein the ester of tocopherol is tocopherol acetate.
6. The method according to claim 4 , wherein the ester of tocopherol has a concentration in the range of approximately 5% to approximately 15% by weight.
7. The method according to claim 1 , further including the step of treating the cyanoacrylate adhesive with selenic acid.
8. A method for increasing the shelf life of a cyanoacrylate adhesive by increasing the stability of the adhesive, the method comprising the following steps:
preparing a cyanoacrylate adhesive; and
treating the cyanoacrylate adhesive with strong acid and as anionic stabilizers and a phenolic free radical stabilizer.
9. The method according to claim 8 , wherein the strong acid is chosen from the group consisting of selenic acid, sulfur dioxide and sulfuric acid.
10. A product formed by a process for fabricating a cyanoacrylate adhesive having improved flexibility, the process comprising the following steps:
preparing a cyanoacrylate adhesive with appropriate stabilizers; and
treating the cyanoacrylate adhesive with an ester of tocopherol at about approximately 5% to approximately 15% loading.
11. The product according to claim 10 , wherein the ester of tocopherol is tocopherol acetate.
12. The product according to claim 10 , further including the following steps:
treating packaging for containment of the cyanoacrylate adhesive or precursors to the cyanoacrylate adhesive with a strong acid; and
introducing the cyanoacrylate adhesive or precursors to the cyanoacrylate adhesive to the packaging.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US10/733,287 US20040127738A1 (en) | 2002-02-20 | 2003-12-12 | Method for curing cyanoacrylate adhesives |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US10/077,852 US20030158579A1 (en) | 2002-02-20 | 2002-02-20 | Method for curing cyanoacrylate adhesives |
| US10/101,346 US6667031B2 (en) | 2002-02-20 | 2002-03-20 | Method for curing cyanoacrylate adhesives |
| US10/733,287 US20040127738A1 (en) | 2002-02-20 | 2003-12-12 | Method for curing cyanoacrylate adhesives |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| US10/101,346 Continuation-In-Part US6667031B2 (en) | 2002-02-20 | 2002-03-20 | Method for curing cyanoacrylate adhesives |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| US20040127738A1 true US20040127738A1 (en) | 2004-07-01 |
Family
ID=27759919
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| US10/733,287 Abandoned US20040127738A1 (en) | 2002-02-20 | 2003-12-12 | Method for curing cyanoacrylate adhesives |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20040127738A1 (en) |
| EP (1) | EP1476170B1 (en) |
| AT (1) | ATE390141T1 (en) |
| AU (1) | AU2003211107A1 (en) |
| CA (1) | CA2484737C (en) |
| WO (1) | WO2003070257A1 (en) |
Cited By (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8198344B2 (en) | 2008-06-20 | 2012-06-12 | Adhezion Biomedical, Llc | Method of preparing adhesive compositions for medical use: single additive as both the thickening agent and the accelerator |
| US8293838B2 (en) | 2008-06-20 | 2012-10-23 | Adhezion Biomedical, Llc | Stable and sterile tissue adhesive composition with a controlled high viscosity |
| US8609128B2 (en) | 2008-10-31 | 2013-12-17 | Adhezion Biomedical, Llc | Cyanoacrylate-based liquid microbial sealant drape |
| US8613952B2 (en) | 2007-11-14 | 2013-12-24 | Adhezion Biomedical, Llc | Cyanoacrylate tissue adhesives |
| US8652510B2 (en) | 2008-10-31 | 2014-02-18 | Adhezion Biomedical, Llc | Sterilized liquid compositions of cyanoacrylate monomer mixtures |
| US8729121B2 (en) | 2007-06-25 | 2014-05-20 | Adhezion Biomedical, Llc | Curing accelerator and method of making |
| US9018254B2 (en) | 2007-06-25 | 2015-04-28 | Adhezion Biomedical, Llc | Cyanoacrylate tissue adhesives with desirable permeability and tensile strength |
| CN105080781A (en) * | 2014-05-22 | 2015-11-25 | 劲捷生物科技股份有限公司 | Coater and method for accelerating adhesive curing reaction |
| US9254133B2 (en) | 2008-10-31 | 2016-02-09 | Adhezion Biomedical, Llc | Sterilized liquid compositions of cyanoacrylate monomer mixtures |
| US9309019B2 (en) | 2010-05-21 | 2016-04-12 | Adhezion Biomedical, Llc | Low dose gamma sterilization of liquid adhesives |
| US9421297B2 (en) | 2014-04-02 | 2016-08-23 | Adhezion Biomedical, Llc | Sterilized compositions of cyanoacrylate monomers and naphthoquinone 2,3-oxides |
| JP2017039832A (en) * | 2015-08-19 | 2017-02-23 | 大原パラヂウム化学株式会社 | A 2-cyanoacrylate adhesive composition containing tocopherol. |
| EP4108226A1 (en) * | 2021-06-22 | 2022-12-28 | Chemence Limited | Nail glue composition |
Citations (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2912454A (en) * | 1957-05-06 | 1959-11-10 | Rohm & Haas | Preparation of alkyl alpha-cyanoacrylates |
| US3667472A (en) * | 1961-10-19 | 1972-06-06 | Borden Inc | Adhesive for living tissue |
| US3903055A (en) * | 1972-12-21 | 1975-09-02 | Johnson & Johnson | Method for initiating polymerization of cyanoacrylate monomers and comonomer blends thereof to give reproducible and predetermined gel/transition time characteristics |
| US3975422A (en) * | 1972-11-21 | 1976-08-17 | Johnson & Johnson | Preparation of bis (2-cyanoacrylate)monomers |
| US3995641A (en) * | 1975-04-23 | 1976-12-07 | Ethicon, Inc. | Surgical adhesives |
| US4003942A (en) * | 1974-10-04 | 1977-01-18 | Johnson & Johnson | Blocked bis 2-cyanoacrylate monomers |
| US4012402A (en) * | 1974-10-04 | 1977-03-15 | Johnson & Johnson | Modified cyanoacrylate monomers and methods for preparation |
| US4013703A (en) * | 1974-10-04 | 1977-03-22 | Johnson & Johnson | Cyanoacrylic acid adducts |
| US4041063A (en) * | 1975-11-18 | 1977-08-09 | Johnson & Johnson | Modified cyanoacrylate monomers and methods of preparation |
| US4057535A (en) * | 1976-04-14 | 1977-11-08 | Tatyana Esperovna Lipatova | Adhesive for gluing together soft body tissues |
| US4182823A (en) * | 1978-08-18 | 1980-01-08 | National Starch And Chemical Corporation | Anionic polymerization inhibitor for cyanoacrylate adhesives |
| US4328170A (en) * | 1978-11-02 | 1982-05-04 | Matsumoto Seiyaku Kogyo Kabushiki Kaisha | Process for preparing an α-cyanoacrylate |
| US4444933A (en) * | 1982-12-02 | 1984-04-24 | Borden, Inc. | Adhesive cyanoacrylate compositions with reduced adhesion to skin |
| US4818325A (en) * | 1985-01-18 | 1989-04-04 | Toagosei Chemical Industry Co., Ltd. | Method of bonding non-polar or highly crystalline resin substrates employing a primer and a cyanoacrylate adhesive |
| US5039753A (en) * | 1987-10-22 | 1991-08-13 | Loctite (Ireland) Ltd | Polymers comprising betadiketone groups and polymerizable compositions containing said polymers |
| US5192536A (en) * | 1990-10-26 | 1993-03-09 | Huprich Carl A | Method and composition for coating a wound with polyether polyurethane |
| US5254132A (en) * | 1992-09-01 | 1993-10-19 | Medlogic, Inc. | Methods for treating suturable wounds by use of sutures and cyanoacrylate adhesives |
| US5328687A (en) * | 1993-03-31 | 1994-07-12 | Tri-Point Medical L.P. | Biocompatible monomer and polymer compositions |
| US5403591A (en) * | 1993-06-25 | 1995-04-04 | Medlogic Global Corporation | Methods for inhibiting skin ulceration by use of cyanoacrylate adhesives |
| US5475110A (en) * | 1994-10-14 | 1995-12-12 | Cephalon, Inc. | Fused Pyrrolocarbazoles |
| US5684042A (en) * | 1997-01-10 | 1997-11-04 | Medlogic Global Corporation | Cyanoacrylate compositions comprising an antimicrobial agent |
| US5749956A (en) * | 1996-08-02 | 1998-05-12 | Loctite Corporation | Non-ozone depleting co-solvent compositions and adhesive promoter compositions based thereon |
| US5807563A (en) * | 1997-01-10 | 1998-09-15 | Medlogic Global Corporation | Methods for draping surgical incision sites |
| US5928611A (en) * | 1995-06-07 | 1999-07-27 | Closure Medical Corporation | Impregnated applicator tip |
| US5944754A (en) * | 1995-11-09 | 1999-08-31 | University Of Massachusetts | Tissue re-surfacing with hydrogel-cell compositions |
| US5981621A (en) * | 1996-02-29 | 1999-11-09 | Closure Medical Corporation | Monomeric compositions effective as wound closure devices |
| US6055828A (en) * | 1997-12-30 | 2000-05-02 | Closure Medical Corporation | Treatment methods for glass medical adhesive applicators |
| US6090397A (en) * | 1997-11-03 | 2000-07-18 | Medlogic Global Corporation | Kits containing cyanoacrylate compositions comprising an antimicrobial agent |
| US6143352A (en) * | 1994-06-28 | 2000-11-07 | Closure Medical Corporation | pH-modified biocompatible monomer and polymer compositions |
| US6143805A (en) * | 1998-02-18 | 2000-11-07 | Closure Medical Corporation | Electron beam sterilization of liquid adhesive compositions |
| US6217603B1 (en) * | 1997-08-29 | 2001-04-17 | Closure Medical Corporation | Methods of applying monomeric compositions effective as wound closure devices |
| US6245933B1 (en) * | 1999-11-19 | 2001-06-12 | Closure Medical Corporation | Transesterification method for making cyanoacrylates |
| US6248800B1 (en) * | 1998-09-18 | 2001-06-19 | Medlogic Global Corporation | Methods for sterilizing cyanoacrylate compositions |
| US6294629B1 (en) * | 1998-11-23 | 2001-09-25 | Loctite (R&D) Limited | Cyanoacrylate compositions |
| US6310166B1 (en) * | 1999-08-12 | 2001-10-30 | Closure Medical Corporation | Sterilized cyanoacrylate solutions containing thickeners |
| US20030077386A1 (en) * | 2001-10-19 | 2003-04-24 | Max Azevedo | Method for curing cyanoacrylate adhesives |
| US6605667B1 (en) * | 2000-09-08 | 2003-08-12 | Closure Medical Corporation | Antioxidant enriched adhesive compositions and storage containers therefor |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IE940864A1 (en) * | 1994-11-04 | 1996-05-15 | Saldane Ltd | Process for the purification of non-enolisable esters |
-
2003
- 2003-02-19 EP EP03742790A patent/EP1476170B1/en not_active Expired - Lifetime
- 2003-02-19 AT AT03742790T patent/ATE390141T1/en not_active IP Right Cessation
- 2003-02-19 WO PCT/US2003/004704 patent/WO2003070257A1/en not_active Ceased
- 2003-02-19 CA CA2484737A patent/CA2484737C/en not_active Expired - Lifetime
- 2003-02-19 AU AU2003211107A patent/AU2003211107A1/en not_active Abandoned
- 2003-12-12 US US10/733,287 patent/US20040127738A1/en not_active Abandoned
Patent Citations (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2912454A (en) * | 1957-05-06 | 1959-11-10 | Rohm & Haas | Preparation of alkyl alpha-cyanoacrylates |
| US3667472A (en) * | 1961-10-19 | 1972-06-06 | Borden Inc | Adhesive for living tissue |
| US3975422A (en) * | 1972-11-21 | 1976-08-17 | Johnson & Johnson | Preparation of bis (2-cyanoacrylate)monomers |
| US3903055A (en) * | 1972-12-21 | 1975-09-02 | Johnson & Johnson | Method for initiating polymerization of cyanoacrylate monomers and comonomer blends thereof to give reproducible and predetermined gel/transition time characteristics |
| US4003942A (en) * | 1974-10-04 | 1977-01-18 | Johnson & Johnson | Blocked bis 2-cyanoacrylate monomers |
| US4012402A (en) * | 1974-10-04 | 1977-03-15 | Johnson & Johnson | Modified cyanoacrylate monomers and methods for preparation |
| US4013703A (en) * | 1974-10-04 | 1977-03-22 | Johnson & Johnson | Cyanoacrylic acid adducts |
| US3995641A (en) * | 1975-04-23 | 1976-12-07 | Ethicon, Inc. | Surgical adhesives |
| US4041063A (en) * | 1975-11-18 | 1977-08-09 | Johnson & Johnson | Modified cyanoacrylate monomers and methods of preparation |
| US4057535A (en) * | 1976-04-14 | 1977-11-08 | Tatyana Esperovna Lipatova | Adhesive for gluing together soft body tissues |
| US4182823A (en) * | 1978-08-18 | 1980-01-08 | National Starch And Chemical Corporation | Anionic polymerization inhibitor for cyanoacrylate adhesives |
| US4328170A (en) * | 1978-11-02 | 1982-05-04 | Matsumoto Seiyaku Kogyo Kabushiki Kaisha | Process for preparing an α-cyanoacrylate |
| US4444933A (en) * | 1982-12-02 | 1984-04-24 | Borden, Inc. | Adhesive cyanoacrylate compositions with reduced adhesion to skin |
| US4818325A (en) * | 1985-01-18 | 1989-04-04 | Toagosei Chemical Industry Co., Ltd. | Method of bonding non-polar or highly crystalline resin substrates employing a primer and a cyanoacrylate adhesive |
| US5039753A (en) * | 1987-10-22 | 1991-08-13 | Loctite (Ireland) Ltd | Polymers comprising betadiketone groups and polymerizable compositions containing said polymers |
| US5192536A (en) * | 1990-10-26 | 1993-03-09 | Huprich Carl A | Method and composition for coating a wound with polyether polyurethane |
| US5254132A (en) * | 1992-09-01 | 1993-10-19 | Medlogic, Inc. | Methods for treating suturable wounds by use of sutures and cyanoacrylate adhesives |
| US5328687A (en) * | 1993-03-31 | 1994-07-12 | Tri-Point Medical L.P. | Biocompatible monomer and polymer compositions |
| US5403591A (en) * | 1993-06-25 | 1995-04-04 | Medlogic Global Corporation | Methods for inhibiting skin ulceration by use of cyanoacrylate adhesives |
| US6143352A (en) * | 1994-06-28 | 2000-11-07 | Closure Medical Corporation | pH-modified biocompatible monomer and polymer compositions |
| US5475110A (en) * | 1994-10-14 | 1995-12-12 | Cephalon, Inc. | Fused Pyrrolocarbazoles |
| US5928611A (en) * | 1995-06-07 | 1999-07-27 | Closure Medical Corporation | Impregnated applicator tip |
| US6099807A (en) * | 1995-06-07 | 2000-08-08 | Closure Medical Corporation | Impregnated applicator tip |
| US5944754A (en) * | 1995-11-09 | 1999-08-31 | University Of Massachusetts | Tissue re-surfacing with hydrogel-cell compositions |
| US5981621A (en) * | 1996-02-29 | 1999-11-09 | Closure Medical Corporation | Monomeric compositions effective as wound closure devices |
| US5749956A (en) * | 1996-08-02 | 1998-05-12 | Loctite Corporation | Non-ozone depleting co-solvent compositions and adhesive promoter compositions based thereon |
| US5684042A (en) * | 1997-01-10 | 1997-11-04 | Medlogic Global Corporation | Cyanoacrylate compositions comprising an antimicrobial agent |
| US6086906A (en) * | 1997-01-10 | 2000-07-11 | Medlogic Global Corporation | Cyanoacrylate compositions comprising an antimicrobial agent |
| US5807563A (en) * | 1997-01-10 | 1998-09-15 | Medlogic Global Corporation | Methods for draping surgical incision sites |
| US6217603B1 (en) * | 1997-08-29 | 2001-04-17 | Closure Medical Corporation | Methods of applying monomeric compositions effective as wound closure devices |
| US6090397A (en) * | 1997-11-03 | 2000-07-18 | Medlogic Global Corporation | Kits containing cyanoacrylate compositions comprising an antimicrobial agent |
| US6055828A (en) * | 1997-12-30 | 2000-05-02 | Closure Medical Corporation | Treatment methods for glass medical adhesive applicators |
| US6143805A (en) * | 1998-02-18 | 2000-11-07 | Closure Medical Corporation | Electron beam sterilization of liquid adhesive compositions |
| US6248800B1 (en) * | 1998-09-18 | 2001-06-19 | Medlogic Global Corporation | Methods for sterilizing cyanoacrylate compositions |
| US6294629B1 (en) * | 1998-11-23 | 2001-09-25 | Loctite (R&D) Limited | Cyanoacrylate compositions |
| US6310166B1 (en) * | 1999-08-12 | 2001-10-30 | Closure Medical Corporation | Sterilized cyanoacrylate solutions containing thickeners |
| US6245933B1 (en) * | 1999-11-19 | 2001-06-12 | Closure Medical Corporation | Transesterification method for making cyanoacrylates |
| US6605667B1 (en) * | 2000-09-08 | 2003-08-12 | Closure Medical Corporation | Antioxidant enriched adhesive compositions and storage containers therefor |
| US20030077386A1 (en) * | 2001-10-19 | 2003-04-24 | Max Azevedo | Method for curing cyanoacrylate adhesives |
Cited By (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8980947B2 (en) | 2007-06-25 | 2015-03-17 | Adhezion Biomedical, Llc | Curing accelerator and method of making |
| US9018254B2 (en) | 2007-06-25 | 2015-04-28 | Adhezion Biomedical, Llc | Cyanoacrylate tissue adhesives with desirable permeability and tensile strength |
| US8729121B2 (en) | 2007-06-25 | 2014-05-20 | Adhezion Biomedical, Llc | Curing accelerator and method of making |
| US8613952B2 (en) | 2007-11-14 | 2013-12-24 | Adhezion Biomedical, Llc | Cyanoacrylate tissue adhesives |
| US8293838B2 (en) | 2008-06-20 | 2012-10-23 | Adhezion Biomedical, Llc | Stable and sterile tissue adhesive composition with a controlled high viscosity |
| US8603451B2 (en) | 2008-06-20 | 2013-12-10 | Adhezion Biomedical, Llc | Adhesive compositions for medical use: single additive as both the thickening agent and the accelerator |
| US8198344B2 (en) | 2008-06-20 | 2012-06-12 | Adhezion Biomedical, Llc | Method of preparing adhesive compositions for medical use: single additive as both the thickening agent and the accelerator |
| US8609128B2 (en) | 2008-10-31 | 2013-12-17 | Adhezion Biomedical, Llc | Cyanoacrylate-based liquid microbial sealant drape |
| US8652510B2 (en) | 2008-10-31 | 2014-02-18 | Adhezion Biomedical, Llc | Sterilized liquid compositions of cyanoacrylate monomer mixtures |
| US9254133B2 (en) | 2008-10-31 | 2016-02-09 | Adhezion Biomedical, Llc | Sterilized liquid compositions of cyanoacrylate monomer mixtures |
| US9309019B2 (en) | 2010-05-21 | 2016-04-12 | Adhezion Biomedical, Llc | Low dose gamma sterilization of liquid adhesives |
| US9421297B2 (en) | 2014-04-02 | 2016-08-23 | Adhezion Biomedical, Llc | Sterilized compositions of cyanoacrylate monomers and naphthoquinone 2,3-oxides |
| CN105080781A (en) * | 2014-05-22 | 2015-11-25 | 劲捷生物科技股份有限公司 | Coater and method for accelerating adhesive curing reaction |
| JP2017039832A (en) * | 2015-08-19 | 2017-02-23 | 大原パラヂウム化学株式会社 | A 2-cyanoacrylate adhesive composition containing tocopherol. |
| EP4108226A1 (en) * | 2021-06-22 | 2022-12-28 | Chemence Limited | Nail glue composition |
Also Published As
| Publication number | Publication date |
|---|---|
| EP1476170B1 (en) | 2008-03-26 |
| WO2003070257A1 (en) | 2003-08-28 |
| AU2003211107A1 (en) | 2003-09-09 |
| CA2484737C (en) | 2011-04-12 |
| ATE390141T1 (en) | 2008-04-15 |
| EP1476170A4 (en) | 2005-07-06 |
| CA2484737A1 (en) | 2003-08-28 |
| EP1476170A1 (en) | 2004-11-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US6667031B2 (en) | Method for curing cyanoacrylate adhesives | |
| US6849082B2 (en) | Method for curing cyanoacrylate adhesives | |
| US20040127738A1 (en) | Method for curing cyanoacrylate adhesives | |
| US6174919B1 (en) | Cyanoacrylate compositions with vinyl terminated ester groups | |
| EP0965623B1 (en) | Stabilized monomer adhesive compositions | |
| CN111094492B (en) | Adhesive composition, adhesive comprising the same, and preparation method thereof | |
| EP0886507B1 (en) | Monomeric compositions effective as wound closure devices | |
| Shantha et al. | Developments and applications of cyanoacrylate adhesives | |
| US6376019B1 (en) | Impregnated applicator tip | |
| US3559652A (en) | Method of adhesively repairing body tissue with alkoxyalkyl 2-cyanoacrylate | |
| AU690303B2 (en) | Ph-modified biocompatible monomer and polymer compositions | |
| US6676322B1 (en) | Impregnated applicator tip | |
| US7932305B2 (en) | Viscous α-cyanoacrylate compositions | |
| WO2008005634A1 (en) | Absorbable cyanoacrylate compositions | |
| CA2301728A1 (en) | Methods of applying monomeric compositions effective as wound closure devices | |
| EP1198530A1 (en) | Flavored cyanoacrylate compositions | |
| CN102112569B (en) | Controlled exotherm of cyanoacrylate formulations | |
| WO2010065289A2 (en) | Medical adhesive compositions | |
| CN102068699A (en) | Medical pressure-sensitive adhesive composition | |
| US20060216266A1 (en) | Absorbable alpha-cyanoacrylate compositions | |
| CN101137356B (en) | Adhesives and Patches | |
| AU2023367263A1 (en) | Stimuli-responsive medical adhesive compositions, articles, and methods | |
| CN102448470A (en) | Controlled exotherm for cyanoacrylate formulations | |
| Raja | Cyanoacrylate adhesives | |
| JPH06346041A (en) | Hydrophilic tacky agent composition |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| AS | Assignment |
Owner name: SPARTAN MEDICAL PRODUCTS, LLC, NEW YORK Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:SPARTAN PRODUCTS, INC.;REEL/FRAME:015641/0868 Effective date: 20040723 |
|
| STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO PAY ISSUE FEE |